<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0906210772
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREVYMIS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LETERMOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20693.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH T/A MSD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH T/A MSD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PREVYMIS is an antiviral prescription medicine that contains the active substance letermovir.</p><p>&nbsp;</p><p>PREVYMIS is a medicine for adults who have recently had a stem cell (bone marrow) transplant or a kidney transplant. The medicine helps stop you from getting ill from CMV (&lsquo;cytomegalovirus&rsquo;).</p><p>&nbsp;</p><p>CMV is a virus. For most people, CMV does not hurt them. However, if your immune system is weak after you get a stem cell transplant or a kidney transplant, you may be at high risk of becoming ill from CMV.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take PREVYMIS if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to letermovir or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you take either of these medicines:</p><p>o&nbsp;&nbsp; pimozide - used for Tourette&rsquo;s syndrome</p><p>o&nbsp;&nbsp; ergot alkaloids (such as ergotamine and dihydroergotamine) - used for migraine headaches.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you take the following herbal product:</p><p>o&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>)</p><p>Do not take PREVYMIS if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before taking PREVYMIS.</p><p><strong>&nbsp;</strong></p><p><strong>If you are taking PREVYMIS with cyclosporine, do not take the following medicines:</strong></p><p>o&nbsp;&nbsp; dabigatran - used for blood clots</p><p>o&nbsp;&nbsp; atorvastatin, simvastatin, rosuvastatin, pitavastatin &ndash;for high cholesterol</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>If you are also taking a medicine for high cholesterol (see list of medicines in section &ldquo;Other medicines and PREVYMIS&rdquo; below) you must tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Your medicine or dose may then need to be changed. See the package leaflet for your other medicine for further information.</p><p>&nbsp;</p><p>Additional blood tests may be needed to monitor the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine, tacrolimus, sirolimus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Voriconazole</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>PREVYMIS is not for use in children and adolescents under 18 years old. This is because PREVYMIS has not been tested in this age group.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Other medicines and PREVYMIS</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because PREVYMIS may affect the way other medicines work, and other medicines may affect how PREVYMIS works. Your doctor or pharmacist will tell you if it is safe to take PREVYMIS with other medicines.</p><p>&nbsp;</p><p>There are some medicines you must not take with PREVYMIS (see list under &ldquo;Do not take PREVYMIS if:&rdquo;).</p><p>There are some additional medicines you must not take with PREVYMIS and cyclosporine (see list under &ldquo;If you are taking PREVYMIS with cyclosporine, do not take the following medicines:&rdquo;).</p><p>&nbsp;</p><p>Also tell your doctor if you are taking any of the following medicines. This is because your doctor may have to change your medicines or change the dose of your medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alfentanil - for severe pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fentanyl - for severe pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinidine - for abnormal heart rhythms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine, tacrolimus, sirolimus - used to prevent transplant rejection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; voriconazole - for fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statins, such as atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin - for high cholesterol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glyburide, repaglinide - for high blood sugar</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenobarbital, phenytoin - for fits or seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dabigatran, warfarin - used to thin the blood or for blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam &ndash; used as a sedative&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amiodarone - used to correct irregular heartbeats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral contraceptive steroids-for birth control</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; omeprazole, pantoprazole &ndash; for stomach ulcers and other stomach<br />problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nafcillin - for bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin - for mycobacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thioridazine - for psychiatric disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan - for high blood pressure in the vessels in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz, etravirine, nevirapine, lopinavir, ritonavir - for HIV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil - for wakefulness</p><p>&nbsp;</p><p>You can ask your doctor or pharmacist for a list of medicines that may interact with PREVYMIS.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. PREVYMIS is not recommended in pregnancy. This is because it has not been studied in pregnancy and it is not known if PREVYMIS will harm your baby while you are pregnant.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>If you are breast‑feeding or are planning to breast-feed, tell your doctor before taking this medicine. Breast-feeding is not recommended while taking PREVYMIS. This is because it is not known if PREVYMIS gets in your breast milk and will be passed to your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>PREVYMIS may have minor influence on your ability to drive and use machines (see section 4 &ldquo;Possible side effects&rdquo; below). Some patients have reported fatigue (feeling very tired) or vertigo (feeling like you are spinning) during treatment with PREVYMIS. If you experience any of these effects, do not drive or use machines until the effect wears off.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>PREVYMIS contains lactose</strong></p><p>PREVYMIS contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p><strong>PREVYMIS contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23&nbsp;mg) per tablet, that isto say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose of &nbsp;PREVYMIS is two 240 mg tablets &nbsp;once a day. If you also take cyclosporine, your doctor will decrease the dose of PREVYMIS to one 240 mg tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take PREVYMIS at the same time every day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take it with or without food.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>How to take</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet(s) whole with some water. Do not break, crush, or chew the tablet.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>If you take more PREVYMIS than you should</strong></p><p>If you take more PREVYMIS than you should, call your doctor straight away.</p><p>&nbsp;</p><p><strong>If you forget to take PREVYMIS</strong></p><p>It is very important that you do not miss or skip doses of PREVYMIS.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose. Take your next dose at the usual time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take two doses of PREVYMIS at the same time to make up for a missed dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not sure what to do, call your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Do not stop taking PREVYMIS</strong></p><p>Do not stop taking PREVYMIS without talking to your doctor first. Do not run out of PREVYMIS. This will give the medicine the best chance to keep you from becoming ill from CMV after you get a &nbsp;stem cell transplant or a kidney transplant.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people</p><p>&bull; diarrhea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (hypersensitivity) &ndash; the signs may include wheezing, difficulty breathing, rashes or hives, itchiness, swelling.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling like you are spinning (vertigo)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormalities in laboratory tests of liver function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood creatinine - shown in blood tests</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired (fatigue)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of hands or feet</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC). SFDA . By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister card after EXP.</p><p>Store below 30&deg;C.Store in the original package in order to protect from moisture.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is letermovir. Each film-coated tablet contains 240 mg letermovir letermovir.</p><p>The other ingredients are:</p><p><u>Tablet core</u></p><p>Microcrystalline cellulose (E460), croscarmellose sodium (E468), povidone (E1201), colloidal anhydrous silica (E551), magnesium stearate (E470b).</p><p><u>Film-coating</u></p><p>Lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518), iron oxide yellow (E172),&nbsp; carnauba wax (E903)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PREVYMIS 240 mg film-coated tablets
PREVYMIS 240 mg film-coated tablet is a yellow oval tablet, debossed with “591” on one side and MSD logo on the other side. The tablet is 16.5 mm long and 8.5 mm wide.
 
The 240 mg tablets are packaged into a carton containing four (4) cardboard cards, each containing a 7-count Polyamide/Aluminium/PVC – Aluminium blister card for a total of 28 tablets.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Merck Sharp &amp; Dohme BV</p><p>Waarderweg 39</p><p>PO Box 581</p><p>2031 BN, 2003 PC</p><p>Haarlem</p><p>Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer&nbsp; </strong></p><p>MSD International GmbH</p><p>T/A MSD Ireland (Ballydine)</p><p>Kilsheelan Clonmel,</p><p>Co. Tipperary</p><p>Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Nov 2023

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بريفمس هو دواء مضاد للفيروسات يحتوي على المادة الفعالة ليتيرموفير.</p><p dir="RTL">يُستخدم بريفمس لدى البالغين ممن خضعوا مؤخّرًا لعملية زرع نخاع العظم. يساعد هذا الدواء على وقايتك من الإصابة بمرض سي إم في CMV (الفيروس المُضخّم للخلايا).</p><p dir="RTL">CMV هو فيروس يوجد لدى الكثير من الناس دون معرفتهم بذلك. عادةً، يبقى CMV في أجسامهم ولا يؤذيهم. ولكن، إذا كان نظام المناعة لديك ضعيفًا بعد إجراء عملية زرع نخاع العظم، فقد تكون أكثر عرضة للإصابة بمرض CMV.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم بريفيميس إذا:</p><p dir="RTL">&bull; كان لديك حساسية نحو ليتيرموفير أو أيّ من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة رقم 6).<br />&bull; كنت تستخدم أحد الأدوية التالية:<br />&nbsp;&nbsp; o&nbsp; بيموزيد - يستخدم لعلاج متلازمة توريت<br />&nbsp;&nbsp; o&nbsp; قلويدات الإرغوت (مثل الإرغوتامين و ديهيدروإرجوتامين) - يستخدم لعلاج الصداع النصفي.</p><p dir="RTL">&bull;كنت تتناول المنتجات العشبية التالية: نبتة القديس يوحنا (Hypericum perforatum)</p><p dir="RTL">لا تستخدم بريفيس إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي أو الممرض قبل أن تستخدم بريفيميس.<br />إذا كنت تستخدم بريفمس مع سيكلوسبورين، لا تستخدم الأدوية التالية:<br />&nbsp;&nbsp; o دابيغاتران - يُستخدم لعلاج جلطات الدم<br />&nbsp;&nbsp; o أتورفاستاتين، سيمفاستاتين، روسوفاستاتين، بيتافاستاتين &ndash; لعلاج ارتفاع الكوليسترول في الدم</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><br />إذا كنت تتناول أيضًا دواء لعلاج ارتفاع نسبة الكوليسترول في الدم (انظر قائمة الأدوية في فقرة &quot;أدوية أخرى و بريفيميس &quot; أدناه) ، يجب عليك إخبار طبيبك على الفور إذا تعرّضت لآلام أو أوجاع في العضلات مجهولة السبب وعلى الأخص إذا كنت تشعر بتوعك أو تعاني من الحمى. قد يحتاج الدواء أو الجرعة إلى تغيير. راجع النشرة الداخلية للدواء للحصول على مزيد من المعلومات.</p><p dir="RTL">قد يتطلب الأمر إجراء فحوصات دم إضافية لمراقبة المنتجات الطبية التالية:</p><p dir="RTL">&bull; السيكلوسبورين، تاكروليموس، سيروليموس<br />&bull; فوريكونازول<br /><br /><strong>الأطفال والمراهقين</strong><br />بريفيميس غير مُعدّ للاستخدام لدى الأطفال والمراهقين دون سن 18 عامًا. وذلك لأنه لم تتم دراسة بريفمس في هذه الفئة العمرية.<br /><br /><strong>الأدوية الأخرى و بريفيميس</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو قد تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى. وذلك لأن بريفيميس قد يؤثر على طريقة عمل الأدوية الأخرى، والأدوية الأخرى قد تؤثر على كيفية عمل بريفمس. سيخبرك طبيبك أو الصيدلي إذا كان من الآمن تناول بريفيميس مع أدوية أخرى.</p><p dir="RTL">هناك بعض الأدوية التي يجب ألا تتناولها مع بريفيميس. انظر القائمة تحت عنوان &quot;لا تستخدم بريفمس إذا كنت تتناول أيّ من هذه الأدوية.&quot;</p><p dir="RTL">أخبر طبيبك أيضًا إذا كنت تتناول أيًا من الأدوية التالية. وذلك لأن طبيبك قد يضطر إلى تغيير الأدوية أو جرعة الأدوية الخاصة بك:</p><p dir="RTL">&bull; ألفنتانيل &ndash; لتسكين الألم الشديد<br />&bull; فنتانيل - لتسكين الألم الشديد<br />&bull; الكينيدين &ndash; لعلاج اضطراب نظم القلب.<br />&bull; السيكلوسبورين، تاكروليموس، سيروليموس - تُستخدم لمنع رفض الزرع<br />&bull; فوريكونازول &nbsp;- لعلاج العدوى الفطرية<br />&bull; الستاتينات، مثل أتورفاستاتين، فلوفاستاتين، روسوفاستاتين، سيمفاستاتين، برافاستاتين، بيتافاستاتين - &nbsp;لعلاج ارتفاع الكوليسترول في الدم<br />&bull; غليبوريد، ريباغلينيد &ndash; لعلاج ارتفاع نسبة السكر في الدم<br />&bull; الفينيتوين كاربامازيبين، فينوباربيتال &ndash; لعلاج النوبات أو التشنجات<br />&bull; دابيغاتران، الوارفارين - يستخدم لزيادة سيولة الدم أو لعلاج التجلطات<br />&bull; ميدازولام - يستخدم كمُسكّن<br />&bull; الأميودارون - يستخدم لتصحيح دقات القلب الغير منتظمة</p><p dir="RTL">&bull; موانع الحمل الفموية - لتحديد النسل<br />&bull; أوميبرازول، بانتوبرازول &ndash; لعلاج قرحة المعدة وغيرها من مشاكل المعدة</p><p dir="RTL">&bull; نافيسلين - للالتهابات البكتيرية</p><p dir="RTL">&nbsp;&bull;ريفابوتين، ريفامبيسين - للالتهابات الفطرية</p><p dir="RTL">&bull; ثيوريدازين - للاضطرابات النفسية</p><p dir="RTL">&bull; بوسينتان - &nbsp;لارتفاع ضغط الدم في الأوعية في الرئتين</p><p dir="RTL">&bull; إيفيفيرينز، إيترافرين، نيفيرابين، لوبينافير، ريتونافير - لفيروس نقص المناعة البشرية</p><p dir="RTL">&nbsp;&bull; مودافينيل - لليقظة</p><p dir="RTL">يمكنك أن تسأل طبيبك أو الصيدلي عن قائمة الأدوية التي قد تتداخل مع بريفمس<br /><br /><strong>الحمل</strong><br />إذا كنتِ حامل، أو تعتقدين أنك قد تكونين حامل، أو تخططين لإنجاب طفل، فاستشيري طبيبك قبل استخدام هذا الدواء. لا يُنصح باستخدام بريفيميس أثناء الحمل. هذا لأنه لم تتم دراسته أثناء الحمل ولا يُعرف إذا كان بريفمس سيؤذي طفلك أثناء الحمل.<br /><br /><strong>الرضاعة الطبيعية</strong><br />إذا كنت ترضعين طفلك أو تخططين للرضاعة الطبيعية، أخبري طبيبك قبل استخدام هذا الدواء. لا يوصى بالرضاعة الطبيعية أثناء تناول بريفيميس. هذا لأنه من غير المعروف إذا كان بريفيميس يُفرز في حليب الثدي وإحتمال إنتقاله إلى طفلك.<br /><br /><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يكون&nbsp; لبريفيميس تأثير بسيط على قدرتك على القيادة واستخدام الآلات (انظر الفقرة 4 - الأعراض الجانبية المحتملة أدناه). أبلغ بعض المرضى عن إصابتهم بالتعب (الشعور بالإرهاق الشديد) أو الدوار (الشعور بأنك تدور) أثناء العلاج ببريفيميس. إذا واجهت أيًّا من هذه التأثيرات، فلا تقود السيارة أو تستخدم الآلات حتى يختفي التأثير.<br />&nbsp;</p><p dir="RTL"><strong>بريفيميس يحتوي على اللاكتوز</strong><br />بريفيميس يحتوي على لاكتوز مونوهيدرات. إذا أخبرك طبيبك بأن لديك عدم تجمّل لبعض السكريات، فاستشر طبيبك قبل تناول هذا المنتج الطبي.</p><p dir="RTL"><strong>يحتوي بريفيميس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) ، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائما حسب إرشادات طبيبك أو الصيدلي تماما. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.<br /><strong>الجرعة</strong>:<br />الجرعة الموصى بها من بريفمس هي قرصان كل منهما 240 ملغم مرة واحدة في اليوم. إذا كنت تتناول سيكلوسبورين أيضًا، فسيقوم طبيبك بتخفيض جرعة بريفمس إلى قرص واحد 240 ملغم مرة واحدة يوميًا.</p><p dir="RTL">&bull; تناول بريفيميس في نفس الوقت كل يوم.<br />&bull; تناوله مع أو بدون الطعام.</p><p dir="RTL"><strong>كيفية تناول الدواء</strong><br />&bull; ابتلع القرص (الأقراص) بالكامل مع بعض الماء. لا تقم بتكسير القرص أو سحقه أو مضغه.<br /><strong>إذا تناولت من بريفيميس أكثر مما يجب</strong><br />إذا تناولت من بريفيميس أكثر مما يجب، أخبر طبيبك على الفور.<br /><strong>إذا نسيت أن تتناول إحدى جرعات بريفيميس</strong></p><p dir="RTL">من المهم جدًّا عدم تفويت أو تخطي جرعات من بريفيميس.</p><p dir="RTL">&bull; إذا نسيت جرعة، تناولها حالما تتذكرها. ومع ذلك، إذا تذكرتها في موعد قريب من موعد الجرعة التالية، تخطى الجرعة الفائتة. تناول الجرعة التالية في الوقت المعتاد.<br />&bull; لا تتناول جرعتين من بريفيمس في نفس الوقت لتعويض جرعة فائتة.<br />&bull; إذا لم تكن متأكدًا مما يجب عليك فعله، راجع طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول بريفيميس</strong><br />لا تتوقف عن تناول بريفيميس دون التحدث إلى طبيبك أولًا. تأكد من عدم نفاد أقراص الدواء منك. سيعطي هذا الدواء أفضل فرصة لمنعك من الإصابة بمرض CMV بعد إجراء عملية زراعة الخلايا الجذعية أو زراعة الكلى.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، مع أنها لا تحدث لدى جميع من يتناوله.</p><p dir="RTL">شائعة: قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص<br />&bull; إسهال<br />&bull; الشعور بالمرض (الغثيان)<br />&bull; المرض (القيء)</p><p>غير شائعة: قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص<br />&bull; تفاعلات تحسسية (فرط الحساسية) - قد تشمل العلامات الصفير، وصعوبة التنفس، والطفح الجلدي أو الشرى، والحكة، والتورم.<br />&bull; فقدان الشهية<br />&bull; التغيرات في حاسة التذوق<br />&bull; صداع الرأس<br />&bull; الدُّوار (الشعور وكأنك تدور)<br />&bull; ألم المعدة<br />&bull; نتائج غير طبيعية في فحوصات وظائف الكبد.<br />&bull; تشنجات العضلات<br />&bull; ارتفاع الكرياتينين في الدم - كما يظهر في فحوصات الدم<br />&bull; الشعور بالتعب الشديد (الإعياء)<br />&bull; تورم اليدان أو القدمان</p><p>&nbsp;</p><p><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا تعرّضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عن طريق (المركز الوطني للتيقظ والسلامة الدوائية التابع للهيئة العامة للغذاء والدواء) . من خلال الإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدرج على علبة الكرتون والقارورة بعد كلمة &quot;EXP &quot;.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p dir="RTL">يُحفظ في العبوة الأصلية للحماية من الرطوبة.</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. من شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات ليتيرموفير<br />المادة الفعالة هي ليتيرموفير. يحتوي كل قرص من الأقراص المُغلّفة بغشاء رقيق على 240 ملغم ليتيرموفير المكونات الأخرى هي:<br /><u>لب القرص</u><br />السليلوز دقيق التبلور (E460)، كروس كارميلوز الصوديوم (E468)، البوفيدون (E1201)، السيليكا اللامائية الغروية (E551)، ستيرات المغنيسيوم (E470b).</p><p><u>طبقة الغشاء الرقيق</u><br />لاكتوز مونوهيدرات، هيبروميلوز(E464)، ثاني أكسيد التيتانيوم (E171)، ثلاثي الأسيتين (E1518)، أكسيد الحديد الأصفر (E172) ، شمع الكرنوبا (E903).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>أقراص بريفمس 240 ملغم المغلفة </u><br />قرص بريفمس 240 ملغم المغلفة عبارة عن قرص بيضاوي أصفر، نُقش عل أحد جانيه الرمز &quot;591&quot; وشعار MSD على الجانب الآخر. يبلغ طول القرص 16,5 مم وعرضه 8,5 مم.&nbsp;</p><p>يتم تغليف الأقراص 240 ملغم في علبة تحتوي على أربع شرائح من الكرتون المقوّى، تحتوي كل منها على 7 بثور مصنوعة من البولي أميد / الألومنيوم / PVC - الألومنيوم ليصبح المجموع 28 قرصًا في كل علبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب و دوم بي في</p><p dir="RTL">واردرويج ٣٩</p><p dir="RTL">صندوق بريد 581</p><p dir="RTL">٢٠٣١ بي ان ،&nbsp; 2003 بي سي</p><p dir="RTL">هارلم</p><p dir="RTL">هولندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">إم إس دي العالمية، شركة ذات مسؤولية محدودة</p><p dir="RTL">تي/أي إم إس دي أيرلندا (باليداين)</p><p dir="RTL">كيلشيلان كلونميل، كو. تيبيراري</p><p dir="RTL">أيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ نوفمبر 2023

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية، الهيئة العامة للغذاء والدواء
فاكس: +966-11-205-7662
للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات . هاتف: +966-11-20382222	
تحويلة: 2317-2356-2353-2354-2334-2340
الهاتف المجاني: 8002490000  
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: www.sfda.gov.sa/npc
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.

(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إنّ الطبيب والصيدلي هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
واتحاد الصيادلة العرب
تمت الموافقة على نشرة معلومات المريض هذه من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PREVYMIS 240 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PREVYMIS 240 mg film-coated tablets

Each film-coated tablet contains 240 mg of letermovir.


Excipients with known effect

Each 240 mg film-coated tablet contains 4 mg of lactose (as monohydrate).

For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

PREVYMIS 240 mg film-coated tablets

Yellow oval tablet of dimensions 16.5 mm x 8.5 mm, debossed with “591” on one side and corporate logo on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).</p><p>&nbsp;</p><p>PREVYMIS is indicated for prophylaxis of CMV disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antiviral agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREVYMIS should be initiated by a physician experienced in the management of patients who have had an allogeneic haematopoietic stem cell transplant or kidney transplant.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Posology</u></p><p>&nbsp;</p><p>PREVYMIS is also available as concentrate for solution for infusion (240&nbsp;mg).</p><p>&nbsp;</p><p>PREVYMIS tablets and concentrate for solution for infusion may be used interchangeably at the discretion of the physician, and no dose adjustment is necessary.</p><p><em>&nbsp;</em></p><p>The recommended dose of PREVYMIS is one 480&nbsp;mg tablet once daily.</p><p>&nbsp;</p><p><em>HSCT</em></p><p>PREVYMIS should be started after HSCT. PREVYMIS may be started on the day of transplant and no later than 28 days post-HSCT. PREVYMIS may be started before or after engraftment. Prophylaxis with PREVYMIS should continue through 100 days post-HSCT.</p><p>&nbsp;</p><p>Prolonged PREVYMIS prophylaxis beyond 100 days post-HSCT may be of benefit in some patients at high risk for late CMV reactivation (see section 5.1).&nbsp;The safety and efficacy of PREVYMIS use for more than 200 days has not been studied in clinical trials.&nbsp;</p><p>&nbsp;</p><p><em>Kidney transplant</em></p><p>PREVYMIS should be started on the day of transplant and no later than 7 days post-kidney transplant and continued through 200 days post-transplant.</p><p>&nbsp;</p><p><em>Dose</em><em> adjustment</em><em> </em></p><p>If PREVYMIS is co-administered with cyclosporine, the dose of PREVYMIS should be decreased to 240&nbsp;mg once daily (see sections 4.5 and 5.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cyclosporine is initiated after starting PREVYMIS, the next dose of PREVYMIS should be decreased to 240&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cyclosporine is discontinued after starting PREVYMIS, the next dose of PREVYMIS should be increased to 480&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cyclosporine dosing is temporarily interrupted due to high cyclosporine levels, no dose adjustment of PREVYMIS is needed.</p><p><em><u>&nbsp;</u></em></p><p><em>Missed dose</em></p><p>Patients should be instructed that if they miss a dose of PREVYMIS, they should take it as soon as they remember. If they do not remember until it is time for the next dose, they should skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed one.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment of PREVYMIS is required based on age (see sections 5.1 and 5.2)<em>.</em></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of PREVYMIS is required based on mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. PREVYMIS is not recommended for patients with severe (Child-Pugh Class C) hepatic impairment (see section 5.2)<em>.</em></p><p>&nbsp;</p><p><em>Combined hepatic and renal impairment</em></p><p>PREVYMIS is not recommended in patients with moderate hepatic impairment combined with moderate or severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of PREVYMIS is recommended for patients with mild, moderate, or severe renal impairment<em>.</em> No dose recommendation can be made for patients with end stage renal disease (ESRD) with or without dialysis. Efficacy and safety has not been demonstrated for patients with ESRD.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of PREVYMIS in patients below 18 years of age have not been established. No data are available (see section 5.1).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For oral use.</p><p>The tablet should be swallowed whole and may be taken with or without food. The tablet should not be divided, crushed, or chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant administration with pimozide (see sections 4.4 and 4.5).
Concomitant administration with ergot alkaloids (see sections 4.4 and 4.5).
Concomitant administration with St. John’s wort (Hypericum perforatum) (see section 4.5).
When letermovir is combined with cyclosporine: 
Concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is contraindicated (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monitoring of CMV DNA</u><u> in HSCT recipients</u></p><p>&nbsp;</p><p>In a Phase 3 trial (P001), the safety and efficacy of letermovir has been established in HSCT patients with a negative CMV DNA test result prior to initiation of prophylaxis. CMV DNA was monitored on a weekly basis until post-transplant Week 14, and subsequently every two weeks until Week 24. In cases of clinically significant CMV DNAemia or disease, letermovir prophylaxis was stopped and standard-of-care pre-emptive therapy (PET) or treatment was initiated. In patients in whom letermovir prophylaxis was initiated and the baseline CMV DNA test was subsequently found to be positive, prophylaxis could be continued if PET criteria had not been met (see section 5.1).<strong><u> </u></strong></p><p><u>&nbsp;</u></p><p><u>Risk of adverse reactions or reduced therapeutic effect due to medicinal product interactions</u></p><p>&nbsp;</p><p>The concomitant use of PREVYMIS and certain medicinal products may result in known or potentially significant medicinal product interactions, some of which may lead to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible clinically significant adverse reactions from greater exposure of concomitant medicinal products or letermovir.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significant decrease of concomitant medicinal product plasma concentrations which may lead to reduced therapeutic effect of the concomitant medicinal product.</p><p>See Table 1 for steps to prevent or manage these known or potentially significant medicinal product interactions, including dosing recommendations (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p>&nbsp;</p><p>PREVYMIS should be used with caution with medicinal products that are CYP3A substrates with narrow therapeutic ranges (e.g., alfentanil, fentanyl, and quinidine) as co-administration may result in increases in the plasma concentrations of CYP3A substrates. Close monitoring and/or dose adjustment of co-administered CYP3A substrates is recommended (see section 4.5).</p><p>&nbsp;</p><p>Increased monitoring of cyclosporine, tacrolimus, sirolimus is generally recommended the first 2 weeks after initiating and ending letermovir (see section 4.5) as well as after changing route of administration of letermovir.</p><p>&nbsp;</p><p>Letermovir is a moderate inducer of enzymes and transporters. Induction may give rise to reduced plasma concentrations of some metabolised and transported medicinal products (see section 4.5). Therapeutic drug monitoring (TDM) is therefore recommended for voriconazole. Concomitant use of dabigatran should be avoided due to risk of reduced dabigatran efficacy.</p><p><u>&nbsp;</u></p><p>Letermovir may increase the plasma concentrations of medicinal products transported by OATP1B1/3 such as many of the statins (see section 4.5 and Table 1).</p><p><u>&nbsp;</u></p><p><u>Excipients</u></p><p><u>&nbsp;</u></p><p>PREVYMIS contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>&nbsp;</u></strong></p><p><u>General information about differences in exposure between different letermovir treatment regimens</u><u> </u></p><p>&nbsp;</p><p>-The estimated letermovir plasma exposure is different depending on the dose regimen used (see table in section 5.2). Therefore, the clinical consequences of drug interactions for letermovir will be dependent on which letermovir regimen is used and whether or not letermovir is combined with cyclosporine.</p><p>-The combination of cyclosporine and letermovir may lead to more marked or additional effects on concomitant medicinal products as compared to letermovir alone (see Table 1).</p><p>&nbsp;</p><p><u>Effect of other medicinal products on letermovir</u></p><p>&nbsp;</p><p>The elimination pathways of letermovir <em>in vivo</em> are biliary excretion and glucuronidation. The relative importance of these pathways is unknown. Both elimination pathways involve active uptake into the hepatocyte through the hepatic uptake transporters OATP1B1/ 3. After uptake, glucuronidation of letermovir is mediated by UGT1A1 and 3. Letermovir also appears to be subject to P-gp and BCRP mediated efflux in the liver and intestine (see section 5.2).</p><p>&nbsp;</p><p><u>Inducers of drug metabolising enzymes or transporters</u></p><p>&nbsp;</p><p>Co-administration of PREVYMIS (with or without cyclosporine) with strong and moderate inducers of transporters (e.g., P-gp) and/or enzymes (e.g., UGTs) is not recommended, as it may lead to subtherapeutic letermovir exposure (see Table 1).&nbsp;</p><p>-Examples of strong inducers include rifampicin, phenytoin, carbamazepine, St. John&rsquo;s wort (<em>Hypericum perforatum</em>), rifabutin and phenobarbital.</p><p>-Examples of moderate inducers include thioridazine, modafinil, ritonavir, lopinavir, efavirenz and etravirine.</p><p>&nbsp;</p><p>Rifampicin co-administration resulted in an initial increase in letermovir plasma concentrations (due to OATP1B1/3 and/or P-gp inhibition) that is not clinically relevant, followed by clinically relevant decreases in letermovir plasma concentrations (due to induction of P-gp/UGT) with continued rifampicin co-administration (see Table 1).<strong> </strong></p><p><u>&nbsp;</u></p><p><u>Additional effects of other products on letermovir relevant when combined with cyclosporine</u></p><p><em>&nbsp;</em></p><p><em>Inhibitors of OATP1B1 or 3</em><em> </em></p><p>Co-administration of PREVYMIS with medicinal products that are inhibitors of OATP1B1/3 transporters may result in increased letermovir plasma concentrations. If PREVYMIS is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of PREVYMIS is 240&nbsp;mg once daily (see Table 1 and sections 4.2 and 5.2). Caution is advised if other OATP1B1/3 inhibitors are added to letermovir combined with cyclosporine.</p><p>-Examples of OATP1B1 inhibitors include gemfibrozil, erythromycin, clarithromycin, and several protease inhibitors (atazanavir, simeprevir).</p><p><strong><u>&nbsp;</u></strong></p><p><em>Inhibitors of P-gp/BCRP</em></p><p><em>In vitro</em> results indicate that letermovir is a substrate of P-gp/BCRP. Changes in letermovir plasma concentrations due to inhibition of P-gp/BCRP by itraconazole were not clinically relevant.</p><p><u>&nbsp;</u></p><p><u>Effect of letermovir on other medicinal products</u></p><p><em>&nbsp;</em></p><p><em>Medicinal products mainly eliminated through metabolism or influenced by active transport </em></p><p>Letermovir is a general inducer<em> in vivo </em>of enzymes and transporters. Unless a particular enzyme or transporter is also inhibited (see below) induction can be expected. Therefore, letermovir may potentially lead to decreased plasma exposure and possibly reduced efficacy of co-administered medicinal products that are mainly eliminated through metabolism or by active transport.</p><p>&nbsp;</p><p>The size of the induction effect is dependent on letermovir route of administration and whether cyclosporine is concomitantly used. The full induction effect can be expected after 10-14 days of letermovir treatment. The time needed to reach steady state of a specific affected medicinal product will also influence the time needed to reach full effect on the plasma concentrations.</p><p><em>&nbsp;</em></p><p><em>In vitro</em>, letermovir is an inhibitor of CYP3A, CYP2C8, CYP2B6, BCRP, UGT1A1, OATP2B1, and OAT3 at <em>in vivo</em> relevant concentrations. <em>In vivo</em> studies are available investigating the net effect on CYP3A4, P-gp, OATP1B1/3 additionally on CYP2C19. The net effect <em>in vivo</em> on the other listed enzymes and transporters is not known. Detailed information is presented below.</p><p>It is unknown whether letermovir may affect the exposure of piperacillin/tazobactam, amphotericine B and micafungin. The potential interaction between letermovir and these medicinal products have not been investigated. There is a theoretical risk of reduced exposure due to induction but the size of the effect and thus clinical relevance is presently unknown.</p><p>&nbsp;</p><p><em>Medicinal products metabolised by CYP3A</em></p><p>Letermovir is a moderate inhibitor of CYP3A <em>in vivo</em>. Co-administration of PREVYMIS with oral midazolam (a CYP3A substrate) results in 2-3-fold increased midazolam plasma concentrations. Co-administration of PREVYMIS may result in clinically relevant increases in the plasma concentrations of co-administered CYP3A substrates (see sections 4.3, 4.4, and 5.2).</p><p>-Examples of such medicinal products include certain immunosuppressants (e.g., cyclosporine, tacrolimus, sirolimus), HMG-CoA reductase inhibitors, and amiodarone (see Table 1). Pimozide and ergot alkaloids are contraindicated (see section 4.3).</p><p>The size of the CYP3A inhibitory effect is dependent on letermovir route of administration and whether cyclosporine is concomitantly used.</p><p>Due to time dependent inhibition and simultaneous induction the net enzyme inhibitory effect may not be reached until after 10-14 days. The time needed to reach steady state of a specific affected medicinal product will also influence the time needed to reach full effect on the plasma concentrations. When ending treatment, it takes 10-14 days for the inhibitory effect to disappear. If monitoring is applied, this is recommended the first 2 weeks after initiating and ending letermovir (see section 4.4) as well as after changing route of letermovir administration.</p><p><em>&nbsp;</em></p><p><em>Medicinal products transported by OATP1B1/3</em></p><p>Letermovir is an inhibitor of OATP1B1/3 transporters<em>.</em> Administration of PREVYMIS may result in a clinically relevant increase in plasma concentrations of co-administered medicinal products that are OATP1B1/3 substrates.</p><p>-Examples of such medicinal products include HMG-CoA reductase inhibitors, fexofenadine, repaglinide and glyburide (see Table 1). Comparing letermovir regimen administered without cyclosporine, the effect is more marked after intravenous than oral letermovir.</p><p>The magnitude of the OATP1B1/3 inhibition on co-administered medicinal products is likely greater when PREVYMIS is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor). This needs to be considered when the letermovir regimen is changed during treatment with an OATP1B1/3 substrate.</p><p>&nbsp;</p><p><em>Medicinal products metabolised by CYP2C9 and/or CYP2C19</em></p><p>Co-administration of PREVYMIS with voriconazole (a CYP2C19 substrate) results in significantly decreased voriconazole plasma concentrations, indicating that letermovir is an inducer of CYP2C19. CYP2C9 is likely also induced. Letermovir has the potential to decrease the exposure of CYP2C9 and/or CYP2C19 substrates potentially resulting in subtherapeutic levels.</p><p>-Examples of such medicinal products include warfarin, voriconazole, diazepam, lansoprazole, omeprazole, esomeprazole, pantoprazole, tilidine, tolbutamide (see Table 1).</p><p>The effect is expected to be less pronounced for oral letermovir without cyclosporine, than intravenous letermovir with or without cyclosporine, or oral letermovir with cyclosporine. This needs to be considered when the letermovir regimen is changed during treatment with a CYP2C9 or CYP2C19 substrate. See also general information on induction above regarding time courses of the interaction.</p><p><em>&nbsp;</em></p><p><em>Medicinal products metabolised by CYP2C8</em></p><p>Letermovir inhibits CYP2C8 <em>in vitro</em> but may also induce CYP2C8 based on its induction potential. The net effect <em>in vivo </em>is unknown.</p><p>-An example of a medicinal product which is mainly eliminated by CYP2C8 is repaglinide (see Table&nbsp;1). Concomitant use of repaglinide and letermovir with or without cyclosporine is not recommended.</p><p>&nbsp;</p><p><em>Medicinal products transported by P-gp in the intestine</em></p><p>Letermovir is an inducer of intestinal P-gp. Administration of PREVYMIS may result in a clinically relevant decrease in plasma concentrations of co-administered medicinal products that are significantly transported by P-gp in the intestine such as dabigatran and sofosbuvir.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Medicinal products metabolised by CYP2B6, UGT1A1 or transported by BCRP or OATP2B1</em></p><p>Letermovir is a general inducer<em> in viv</em>o but has also been observed to inhibit CYP2B6, UGT1A1, BCRP, and OATP2B1<em> in vitro</em>. The net effect <em>in vivo</em> is unknown. Therefore, the plasma concentrations of medicinal products that are substrates of these enzymes or transporters may increase or decrease when co-administered with letermovir. Additional monitoring may be recommended; refer to the prescribing information for such medicinal products.</p><p>- Examples of medicinal products that are metabolised by CYP2B6 include bupropion.</p><p>- Examples of medicinal products metabolised by UGT1A1 are raltegravir and dolutegravir.</p><p>- Examples of medicinal products transported by BCRP include rosuvastatin and sulfasalazine.</p><p>- An example of a medicinal product transported by OATP2B1 is celiprolol.</p><p>&nbsp;</p><p><em>Medicinal products transported by the renal transporter OAT3</em></p><p><em>In vitro</em> data indicate that letermovir is an inhibitor of OAT3; therefore, letermovir may be an OAT3 inhibitor <em>in vivo</em>. Plasma concentrations of medicinal products transported by OAT3 may be increased.</p><p>-Examples of medicinal products transported by OAT3 includes ciprofloxacin, tenofovir, imipenem, and cilastin.</p><p><u>&nbsp;</u></p><p><u>General information</u></p><p>&nbsp;</p><p>If dose adjustments of concomitant medicinal products are made due to treatment with PREVYMIS, doses should be readjusted after treatment with PREVYMIS is completed. A dose adjustment may also be needed when changing route of administration or immunosuppressant.</p><p>&nbsp;</p><p>Table 1 provides a listing of established or potentially clinically significant medicinal product interactions. The medicinal product interactions described are based on studies conducted with PREVYMIS or are predicted medicinal product interactions that may occur with PREVYMIS (see sections 4.3, 4.4, 5.1, and 5.2).</p><p>&nbsp;</p><p><strong>Table 1: Interactions and dose recommendations with other medicinal products. Note that the table is not extensive but provides examples of clinically relevant interactions. See also the general text on DDIs above.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Unless otherwise specified, interaction studies have been performed with oral letermovir without cyclosporine. Please note that the interaction potential and clinical consequences may be different depending on whether letermovir is administered orally or intravenous, and whether cyclosporine is concomitantly used. When changing the route of administration, or if changing immunosuppressant, the recommendation concerning co-administration should be revisited. </strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Concomitant medicinal product </strong></p></td><td style="vertical-align:top"><p><strong>Effect on concentration</strong><sup>&dagger;</sup><strong> </strong><strong>Mean ratio (90 % confidence interval) for AUC, C<sub>max</sub></strong><strong> (likely mechanism of action)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co-administration with PREVYMIS</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Antibiotics</strong></p></td></tr><tr><td style="vertical-align:top"><p>nafcillin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Nafcillin may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and nafcillin is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antifungals</strong></p></td></tr><tr><td style="vertical-align:top"><p>fluconazole</p><p>(400&nbsp;mg single dose)/letermovir (480&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&harr; fluconazole</p><p>AUC 1.03 (0.99, 1.08)</p><p>C<sub>max</sub> 0.95 (0.92, 0.99)</p><p>&harr; letermovir</p><p>AUC 1.11 (1.01, 1.23)</p><p>C<sub>max </sub>1.06 (0.93, 1.21)</p><p>&nbsp;</p><p>Interaction at steady state not studied.</p><p>Expected;</p><p>&harr; fluconazole</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>itraconazole</p><p>(200&nbsp;mg once daily PO)/letermovir (480&nbsp;mg once daily PO)</p></td><td style="vertical-align:top"><p>&harr; itraconazole</p><p>AUC 0.76 (0.71, 0.81)</p><p>C<sub>max</sub> 0.84 (0.76, 0.92)</p><p>&nbsp;</p><p>&harr; letermovir<br />AUC 1.33 (1.17, 1.51)</p><p>C<sub>max</sub> 1.21 (1.05, 1.39)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td style="vertical-align:top"><p>posaconazole<sup>&Dagger;</sup></p><p>(300&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr; posaconazole</p><p>AUC 0.98 (0.82, 1.17)</p><p>C<sub>max</sub> 1.11 (0.95, 1.29)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>voriconazole<sup>&Dagger;</sup></p><p>(200&nbsp;mg twice daily)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&darr; voriconazole</p><p>AUC 0.56 (0.51, 0.62)</p><p>C<sub>max</sub> 0.61 (0.53, 0.71)</p><p>&nbsp;</p><p>(CYP2C9/19 induction)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>If concomitant administration is necessary, TDM for voriconazole is recommended the first 2 weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir or immunosuppressant.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antimycobacterials</strong></p></td></tr><tr><td style="vertical-align:top"><p>rifabutin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Rifabutin may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and rifabutin is not recommended.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>rifampicin</p></td><td rowspan="5"><p>Multiple dose rifampicin decreases plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and rifampicin is not recommended.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg single dose PO)/ letermovir (480&nbsp;mg single dose PO)</p></td><td style="vertical-align:top"><p>&harr;letermovir</p><p>AUC 2.03 (1.84, 2.26)</p><p>C<sub>max</sub> 1.59 (1.46, 1.74)</p><p>C<sub>24</sub> 2.01 (1.59, 2.54)</p><p>&nbsp;</p><p>(OATP1B1/3 and/or P-gp inhibition)</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg single dose intravenous)/ letermovir (480&nbsp;mg single dose PO)</p></td><td style="vertical-align:top"><p>&harr; letermovir</p><p>AUC 1.58 (1.38, 1.81)</p><p>C<sub>max</sub> 1.37 (1.16, 1.61)</p><p>C<sub>24 </sub>0.78 (0.65, 0.93)</p><p>&nbsp;</p><p>(OATP1B1/3 and/or P-gp inhibition)</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg once daily PO)/ letermovir (480&nbsp;mg once daily PO)</p></td><td style="vertical-align:top"><p>&darr; letermovir</p><p>AUC 0.81 (0.67, 0.98)</p><p>C<sub>max</sub> 1.01 (0.79, 1.28)</p><p>C<sub>24 </sub>0.14 (0.11, 0.19)</p><p>&nbsp;</p><p>(Sum of OATP1B1/3 and/or P-gp inhibition and P-gp/UGT induction)</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg once daily PO (24&nbsp;hours after rifampicin))<sup>&sect;</sup>/ letermovir (480&nbsp;mg once daily PO)</p></td><td style="vertical-align:top"><p>&darr; letermovir</p><p>AUC 0.15 (0.13, 0.17)</p><p>C<sub>max</sub> 0.27 (0.22, 0.31)</p><p>C<sub>24 </sub>0.09 (0.06, 0.12)</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antipsychotics</strong></p></td></tr><tr><td style="vertical-align:top"><p>thioridazine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Thioridazine may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and thioridazine is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Endothelin antagonists</strong></p></td></tr><tr><td style="vertical-align:top"><p>bosentan</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Bosentan may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and bosentan is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antivirals</strong></p></td></tr><tr><td style="vertical-align:top"><p>acyclovir<sup>&Dagger;</sup></p><p>(400&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr; acyclovir</p><p>AUC 1.02 (0.87, 1.2)</p><p>C<sub>max</sub> 0.82 (0.71, 0.93)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>valacyclovir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&harr; valacyclovir</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Herbal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s wort (<em>Hypericum perforatum</em>)</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>St. John&rsquo;s wort may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and St. John&rsquo;s wort is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HIV medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>(P-gp/UGT induction)</p><p>&nbsp;</p><p>&uarr; or &darr; efavirenz</p><p>(CYP2B6 inhibition or induction)</p></td><td style="vertical-align:top"><p>Efavirenz may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and efavirenz is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>etravirine, nevirapine, ritonavir, lopinavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>These antivirals may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS with these antivirals is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HMG-CoA reductase inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p>atorvastatin<sup>&Dagger;</sup></p><p>(20&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; atorvastatin</p><p>AUC 3.29 (2.84, 3.82)</p><p>C<sub>max</sub> 2.17 (1.76, 2.67)</p><p>&nbsp;</p><p>(CYP3A, OATP1B1/3 inhibition)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Statin-associated adverse events such as myopathy should be closely monitored. The dose of atorvastatin should not exceed 20&nbsp;mg daily when co-administered with PREVYMIS<sup>#</sup>.</p><p>&nbsp;</p><p>Although not studied, when PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in atorvastatin plasma concentrations is expected to be greater than with PREVYMIS alone.</p><p>When PREVYMIS is co-administered with cyclosporine, atorvastatin is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>simvastatin, pitavastatin,</p><p>rosuvastatin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; HMG-CoA reductase inhibitors</p><p>&nbsp;</p><p>(CYP3A, OATP1B1/3 inhibition)</p></td><td style="vertical-align:top"><p>Letermovir may substantially increase plasma concentrations of these statins. Concomitant use is not recommended with PREVYMIS alone.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, use of these statins is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>fluvastatin, pravastatin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; HMG-CoA reductase inhibitors</p><p>&nbsp;</p><p>(OATP1B1/3 and/or BCRP inhibition)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir may increase statin plasma concentrations.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with these statins, a statin dose reduction may be necessary<sup>#</sup>. Statin-associated adverse events such as myopathy should be closely monitored.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, pravastatin is not recommended while for fluvastatin, a dose reduction may be necessary<sup>#</sup>. Statin-associated adverse events such as myopathy should be closely monitored.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immunosuppressants</strong></p></td></tr><tr><td style="vertical-align:top"><p>cyclosporine</p><p>(50&nbsp;mg single dose)/ letermovir (240&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; cyclosporine</p><p>AUC 1.66 (1.51, 1.82)</p><p>C<sub>max</sub> 1.08 (0.97, 1.19)</p><p>(CYP3A inhibition)</p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>If PREVYMIS is co-administered with cyclosporine, the dose of PREVYMIS should be decreased to 240&nbsp;mg once daily (see sections 4.2 and 5.1).</p><p>&nbsp;</p><p>Frequent monitoring of cyclosporine whole blood concentrations should be performed during treatment, when changing PREVYMIS administration route, and at discontinuation of PREVYMIS and the dose of cyclosporine adjusted accordingly<sup>#</sup>.<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>cyclosporine</p><p>(200&nbsp;mg single dose)/ letermovir (240&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; letermovir</p><p>AUC 2.11 (1.97, 2.26)</p><p>C<sub>max</sub> 1.48 (1.33, 1.65)</p><p>&nbsp;</p><p>(OATP1B1/3 inhibition)</p></td></tr><tr><td style="vertical-align:top"><p>mycophenolate mofetil</p><p>(1 g single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr;mycophenolic acid</p><p>AUC 1.08 (0.97, 1.20)</p><p>C<sub>max</sub> 0.96 (0.82, 1.12)</p><p>&nbsp;</p><p>&harr; letermovir</p><p>AUC 1.18 (1.04, 1.32)</p><p>C<sub>max</sub> 1.11 (0.92, 1.34)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>sirolimus<sup>&Dagger;</sup></p><p>(2&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; sirolimus</p><p>AUC 3.40 (3.01, 3.85)</p><p>C<sub>max</sub> 2.76 (2.48, 3.06)</p><p>&nbsp;</p><p>(CYP3A inhibition)</p><p>&nbsp;</p><p>Interaction not studied.</p><p>Expected:</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>Frequent monitoring of sirolimus whole blood concentrations should be performed during treatment, when changing PREVYMIS administration route, and at discontinuation of PREVYMIS and the dose of sirolimus adjusted accordingly<sup>#</sup>.</p><p>Frequent monitoring of sirolimus concentrations is recommended at initiation or discontinuation of cyclosporine co-administration with PREVYMIS.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, also refer to the sirolimus prescribing information for specific dosing recommendations for use of sirolimus with cyclosporine.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in concentrations of sirolimus may be greater than with PREVYMIS alone.</p></td></tr><tr><td style="vertical-align:top"><p>tacrolimus</p><p>(5&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; tacrolimus</p><p>AUC 2.42 (2.04, 2.88)</p><p>C<sub>max</sub> 1.57 (1.32, 1.86)</p><p>(CYP3A inhibition)</p></td><td rowspan="2" style="vertical-align:top"><p>Frequent monitoring of tacrolimus whole blood concentrations should be performed during treatment, when changing PREVYMIS administration route, and at discontinuation of PREVYMIS and the dose of tacrolimus adjusted accordingly<sup>#</sup>.<sup> </sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>tacrolimus</p><p>(5&nbsp;mg single dose)/ letermovir (80&nbsp;mg twice daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; letermovir</p><p>AUC 1.02 (0.97, 1.07)</p><p>C<sub>max</sub> 0.92 (0.84, 1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Oral contraceptives</strong></p></td></tr><tr><td style="vertical-align:top"><p>ethinylestradiol (EE) (0.03&nbsp;mg)/ levonorgestrel (LNG)<sup>&Dagger;</sup></p><p>(0.15&nbsp;mg) single dose/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr; EE</p><p>AUC 1.42 (1.32, 1.52)</p><p>C<sub>max</sub> 0.89 (0.83, 0.96)</p><p>&nbsp;</p><p>&harr; LNG</p><p>AUC 1.36 (1.30, 1.43)</p><p>C<sub>max</sub> 0.95 (0.86, 1.04)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Other systemically acting oral contraceptive steroids</p></td><td style="vertical-align:top"><p>Risk of &darr; contraceptive steroids</p></td><td style="vertical-align:top"><p>Letermovir may reduce plasma concentrations of other oral contraceptive steroids thereby affecting their efficacy.</p><p>For adequate contraceptive effect to be ensured with an oral contraceptive, products containing EE and LNG should be chosen.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antidiabetic medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>repaglinide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; or &darr; repaglinide</p><p>&nbsp;</p><p>(CYP2C8 induction, CYP2C8 and OATP1B inhibition)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir may increase or decrease the plasma concentrations of repaglinide. (The net effect is not known).</p><p>&nbsp;</p><p>Concomitant use is not recommended.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, the plasma concentrations of repaglinide is expected to increase due to the additional OATP1B inhibition by cyclosporine. Concomitant use is not recommended<sup>#</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>glyburide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; glyburide</p><p>&nbsp;</p><p>(OATP1B1/3 inhibition CYP3A inhibition, CYP2C9 induction)</p></td><td style="vertical-align:top"><p>Letermovir may increase the plasma concentrations of glyburide.</p><p>&nbsp;</p><p>Frequent monitoring of glucose concentrations is recommended the first 2&nbsp;weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, refer also to the glyburide prescribing information for specific dosing recommendations.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiepileptic medicinal products (see also general text)</strong></p></td></tr><tr><td style="vertical-align:top"><p>carbamazepine,<br />phenobarbital</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Carbamazepine or phenobarbital may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and carbamazepine or phenobarbital is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>phenytoin</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p><p>&nbsp;</p><p>&darr; phenytoin</p><p>&nbsp;</p><p>(CYP2C9/19 induction)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phenytoin may decrease plasma concentrations of letermovir.</p><p>&nbsp;</p><p>Letermovir may decrease the plasma concentrations of phenytoin.</p><p>&nbsp;</p><p>Co-administration of PREVYMIS and phenytoin is not recommended.</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Oral anticoagulants</strong></p></td></tr><tr><td style="vertical-align:top"><p>warfarin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; warfarin</p><p>&nbsp;</p><p>(CYP2C9 induction)</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of warfarin.</p><p>&nbsp;</p><p>Frequent monitoring of International Normalised Ratio (INR) should be performed when warfarin is co-administered with PREVYMIS treatment<sup>#</sup>. Monitoring is recommended the first 2&nbsp;weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir or immunosuppressant.</p></td></tr><tr><td style="vertical-align:top"><p>dabigatran</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; dabigatran</p><p>&nbsp;</p><p>(intestinal P-gp induction)</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of dabigatran and may decrease efficacy of dabigatran. Concomitant use of dabigatran should be avoided due to the risk of reduced dabigatran efficacy.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, dabigatran is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Sedatives</strong></p></td></tr><tr><td style="vertical-align:top"><p>midazolam</p><p>(1&nbsp;mg single dose intravenous)/ letermovir (240&nbsp;mg once daily PO)</p><p>&nbsp;</p><p>midazolam (2&nbsp;mg single dose PO) / letermovir (240&nbsp;mg once daily PO)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&uarr; midazolam</p><p>intravenous:</p><p>AUC 1.47 (1.37, 1.58)</p><p>C<sub>max</sub> 1.05 (0.94, 1.17)</p><p>&nbsp;</p><p>PO:</p><p>AUC 2.25 (2.04, 2.48)</p><p>C<sub>max</sub> 1.72 (1.55, 1.92)</p><p>&nbsp;</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during co-administration of PREVYMIS with midazolam. Dose adjustment of midazolam should be considered<sup>#</sup>. The increase in midazolam plasma concentration may be greater when oral midazolam is administered with letermovir at the clinical dose than with the dose studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Opioid agonists</strong></p></td></tr><tr><td style="vertical-align:top"><p>Examples: alfentanil, fentanyl</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; CYP3A metabolised opioids</p><p>&nbsp;</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Frequent monitoring for adverse reactions related to these medicinal products is recommended during co-administration. Dose adjustment of CYP3A metabolised opioids may be needed<sup>#</sup> (see section 4.4).</p><p>Monitoring is also recommended if changing route of administration. When PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in plasma concentrations of CYP3A metabolised opioids may be greater. Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during co-administration of PREVYMIS in combination with cyclosporine and alfentanil or fentanyl. Refer to the respective prescribing information (see section 4.4).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-arrhythmic medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>amiodarone</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; amiodarone</p><p>&nbsp;</p><p>(primarily CYP3A inhibition and CYP2C8 inhibition or induction)</p></td><td style="vertical-align:top"><p>Letermovir may increase the plasma concentrations of amiodarone.</p><p>&nbsp;</p><p>Frequent monitoring for adverse reactions related to amiodarone is recommended during co-administration. Monitoring of amiodarone concentrations should be performed regularly when amiodarone is co-administered with PREVYMIS<sup>#</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>quinidine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; quinidine</p><p>&nbsp;</p><p>(CYP3A inhibition)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir may increase the plasma concentrations of quinidine.</p><p>&nbsp;</p><p>Close clinical monitoring should be exercised during administration of PREVYMIS with quinidine. Refer to the respective prescribing information<sup>#</sup>.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>digoxin<sup>&Dagger;</sup></p><p>(0.5&nbsp;mg single dose)/ letermovir (240&nbsp;mg twice daily)</p></td><td style="vertical-align:top"><p>&harr; digoxin</p><p>AUC 0.88 (0.80, 0.96)</p><p>C<sub>max</sub> 0.75 (0.63, 0.89)</p><p>&nbsp;</p><p>(P-gp induction)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proton pump inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p>omeprazole</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr;omeprazole</p><p>&nbsp;</p><p>(induction of CYP2C19)</p><p>&nbsp;</p><p>Interaction not studied.</p><p>Expected:</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of CYP2C19 substrates.</p><p>&nbsp;</p><p>Clinical monitoring and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>pantoprazole</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; pantoprazole</p><p>&nbsp;</p><p>(likely due to induction of CYP2C19)</p><p>&nbsp;</p><p>Interaction not studied.</p><p>Expected:</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of CYP2C19 substrates.</p><p>&nbsp;</p><p>Clinical monitoring and dose adjustment may be needed.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Wakefulness-promoting agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>modafinil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Modafinil may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and modafinil is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*This table is not all inclusive.</p><p><strong><sup>&dagger;</sup></strong> &darr; =decrease, &uarr; =increase</p><p>&harr; =no clinically relevant change</p><p><sup>&Dagger; </sup>One-way interaction study assessing the effect of letermovir on the concomitant medicinal product.</p><p><sup>&sect; </sup>These data are the effect of rifampicin on letermovir 24 hours after final rifampicin dose.</p><p><sup>#</sup>Refer to the respective prescribing information.</p><p>&nbsp;</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of letermovir in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>PREVYMIS is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether letermovir is excreted in human milk.</p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of letermovir in milk (see section 5.3).</p><p>A risk to the newborns/infants cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from PREVYMIS therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There were no effects on female fertility in rats. Irreversible testicular toxicity and impairment of fertility was observed in male rats, but not in male mice or male monkeys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREVYMIS may have minor influence on the ability to drive or use machines. Fatigue and vertigo have been reported in some patients during treatment with PREVYMIS, which may influence a patient&rsquo;s ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety assessment of PREVYMIS was based on three Phase 3 clinical trials.</p><p>&nbsp;</p><p><em>HSCT</em></p><p>In P001, 565 HSCT recipients received PREVYMIS or placebo through Week 14 post-transplant and were followed for safety through Week 24 post-transplant (see section 5.1). The most commonly reported adverse reactions occurring in at least 1% of subjects in the PREVYMIS group and at a frequency greater than placebo were: nausea (7.2%), diarrhoea (2.4%), and vomiting (1.9%). The most frequently reported adverse reactions that led to discontinuation of PREVYMIS were: nausea (1.6%), vomiting (0.8%), and abdominal pain (0.5%).</p><p>&nbsp;</p><p>In P040, 218 HSCT recipients received PREVYMIS or placebo from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT and were followed for safety through Week 48 post-HSCT (see section 5.1). The adverse reactions reported were consistent with the safety profile of PREVYMIS as characterised in study P001.</p><p>&nbsp;</p><p><em>Kidney transplant</em></p><p>In P002, 292 kidney transplant recipients received PREVYMIS through Week 28 (~200 days) post-transplant (see section 5.1).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions were identified in patients taking PREVYMIS in clinical trials. The adverse reactions are listed below by body system organ class and frequency. Frequencies are defined as follows: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) or very rare (&lt; 1/10,000).</p><p>&nbsp;</p><p><strong>Table 2: Adverse reactions identified with PREVYMIS</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>decreased appetite</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>dysgeusia, headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>nausea, diarrhoea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>alanine aminotransferase increased, aspartate aminotransferase increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>muscle spasms</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood creatinine increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>fatigue, oedema peripheral</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with human overdose with PREVYMIS. During Phase 1 clinical trials, 86 healthy subjects received doses ranging from 720&nbsp;mg/day to 1440&nbsp;mg/day of PREVYMIS for up to 14 days. The adverse reaction profile was similar to that of the clinical dose of 480&nbsp;mg/day. There is no specific antidote for overdose with PREVYMIS. In case of overdose, it is recommended that the patient be monitored for adverse reactions and appropriate symptomatic treatment instituted.</p><p>&nbsp;</p><p>It is unknown whether dialysis will result in meaningful removal of PREVYMIS from systemic circulation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, ATC code: J05AX18</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Letermovir inhibits the CMV DNA terminase complex which is required for cleavage and packaging of viral progeny DNA. Letermovir affects the formation of proper unit length genomes and interferes with virion maturation.</p><p><u>&nbsp;</u></p><p><u>Antiviral activity</u></p><p>&nbsp;</p><p>The median EC<sub>50 </sub>value of letermovir against a collection of clinical CMV isolates in a cell-culture model of infection was 2.1&nbsp;nM (range=0.7&nbsp;nM to 6.1&nbsp;nM, n=74).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><u>Viral resistance</u></p><p><em>&nbsp;</em></p><p><em>In cell culture</em></p><p>The CMV genes UL51, UL56, and UL89 encode subunits of CMV DNA terminase. CMV mutants with reduced susceptibility to letermovir have been confirmed in cell culture. EC<sub>50</sub> values for recombinant CMV mutants expressing the substitutions map to pUL51 (P91S), pUL56 (C25F, S229F, V231A, V231L, V236A, T244K, T244R, L254F, L257F, L257I, F261C, F261L, F261S, Y321C, L328V, M329T, A365S, N368D), and pUL89 (N320H, D344E) were 1.6- to &lt;10-fold higher than those for wild-type reference virus; these substitutions are not likely to be clinically relevant. EC<sub>50</sub> values for recombinant CMV mutants expressing pUL51 substitution A95V or pUL56 substitutions N232Y, V236L, V236M, E237D, E237G, L241P, K258E, C325F, C325R, C325W, C325Y, R369G, R369M, R369S and R369T were 10- to 9,300-fold higher than those for the wild-type reference virus; some of these substitutions have been observed in patients who have experienced prophylaxis failure in clinical trials (see below).</p><p>&nbsp;</p><p><em>In clinical </em><em>trials</em></p><p>In a Phase 2b trial evaluating letermovir doses of 60, 120, or 240&nbsp;mg/day or placebo for up to 84 days in 131 HSCT recipients, DNA sequence analysis of a select region of UL56 (amino acids 231 to 369) was performed on samples obtained from 12 letermovir-treated subjects who experienced prophylaxis failure and for whom samples were available for analysis. One subject (who received 60&nbsp;mg/day) had a letermovir resistant genotypic variant (GV) (V236M).</p><p>&nbsp;</p><p>In a Phase 3 trial (P001), DNA sequence analysis of the entire coding regions of UL56 and UL89 was performed on samples obtained from 40 letermovir-treated subjects in the FAS population who experienced prophylaxis failure and for whom samples were available for analysis. Two subjects had letermovir-resistant GVs detected, both with substitutions mapping to pUL56. One subject had the substitution V236M and the other subject had the substitution E237G. One additional subject, who had detectable CMV DNA at baseline (and was therefore not in the FAS population), had pUL56 substitutions, C325W and R369T, detected after discontinuing letermovir.</p><p>&nbsp;</p><p>In a Phase 3 trial (P040), DNA sequence analysis of the entire coding regions of UL51, UL56 and UL89 was performed on samples obtained from 32 subjects (regardless of treatment group) who experienced prophylaxis failure or who discontinued early with CMV viremia. There were no letermovir resistance-associated substitutions detected above the validated assay limit of 5%.</p><p>&nbsp;</p><p>In a Phase 3 trial (P002), DNA sequence analysis of the entire coding regions of UL51, UL56 and UL89 was performed on samples obtained from 52 letermovir-treated subjects who experienced CMV disease or who discontinued early with CMV viremia. There were no letermovir resistance-associated substitutions detected above the validated assay limit of 5%.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Cross-resistance</u></p><p>&nbsp;</p><p>Cross-resistance is not likely with medicinal products with a different mechanism of action. Letermovir is fully active against viral populations with substitutions conferring resistance to CMV DNA polymerase inhibitors (ganciclovir, cidofovir, and foscarnet). A panel of recombinant CMV strains with substitutions conferring resistance to letermovir was fully susceptible to cidofovir, foscarnet and ganciclovir with the exception of a recombinant strain with the pUL56 E237G substitution which confers a 2.1-fold reduction in ganciclovir susceptibility relative to wild-type.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Cardiac electrophysiology</u></p><p>&nbsp;</p><p>The effect of letermovir on doses up to 960&nbsp;mg given intravenous on the QTc interval was evaluated in a randomised, single-dose, placebo- and active-controlled (moxifloxacin 400&nbsp;mg oral) 4-period crossover thorough QT trial in 38 healthy subjects. Letermovir does not prolong QTc to any clinically relevant extent following the 960&nbsp;mg intravenous dose with plasma concentrations approximately 2-fold higher than the 480&nbsp;mg intravenous dose.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant</em></p><p><em>&nbsp;</em></p><p><em>P001: Prophylaxis through Week 14 (~100 days) post-HSCT</em></p><p>To evaluate letermovir prophylaxis as a preventive strategy for CMV infection or disease, the efficacy of letermovir was assessed in a multicentre, double-blind, placebo-controlled Phase 3 trial (P001) in adult CMV-seropositive recipients [R+] of an allogeneic HSCT. Subjects were randomised (2:1) to receive either letermovir at a dose of 480&nbsp;mg once daily adjusted to 240&nbsp;mg when co-administered with cyclosporine, or placebo. Randomisation was stratified by investigational site and risk (high vs. low) for CMV reactivation at the time of study entry. Letermovir was initiated after HSCT (Day 0-28 post-HSCT) and continued through Week 14 post-HSCT. Letermovir was administered either orally or intravenous; the dose of letermovir was the same regardless of the route of administration. Subjects were monitored through Week 24 post-HSCT for the primary efficacy endpoint with continued follow-up through Week 48 post-HSCT.</p><p><strong>&nbsp;</strong></p><p>Subjects received CMV DNA monitoring weekly until post-HSCT week 14 and then every two weeks until post-HSCT week 24, with initiation of standard-of-care CMV pre-emptive therapy if CMV DNAemia was considered clinically significant. Subjects had continued follow-up through Week 48 post-HSCT.</p><p>&nbsp;</p><p>Among the 565 treated subjects, 373 subjects received letermovir (including 99 subjects who received at least one intravenous dose) and 192 received placebo (including 48 subjects who received at least one intravenous dose). The median time to starting letermovir was 9 days after transplantation. Thirty-seven percent (37%) of subjects were engrafted at baseline. The median age was 54 years (range: 18 to 78 years); 56 (15.0%) subjects were 65 years of age or older: 58% were male; 82% were White; 10% were Asian; 2% were Black or African; and 7% were Hispanic or Latino. At baseline, 50% of subjects received a myeloablative regimen, 52% were receiving cyclosporine, and 42% were receiving tacrolimus. The most common primary reasons for transplant were acute myeloid leukaemia (38%), myeloblastic syndrome (15%), and lymphoma (13%). Twelve percent (12%) of subjects were positive for CMV DNA at baseline.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p>At baseline, 31% of subjects were at high risk for reactivation as defined by one or more of the following criteria: Human Leucocyte Antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B or &ndash;DR, haploidentical donor; unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1; use of umbilical cord blood as stem cell source; use of <em>ex vivo</em> T-cell-depleted grafts; Grade 2 or greater Graft-Versus-Host Disease (GVHD), requiring systemic corticosteroids.</p><p>&nbsp;</p><p><em>Primary efficacy endpoint</em></p><p>The primary efficacy endpoint of clinically significant CMV infection in P001 was defined by the incidence of CMV DNAemia warranting anti-CMV pre-emptive therapy (PET) or the occurrence of CMV end-organ disease. The Non-Completer=Failure (NC=F) approach was used, where subjects who discontinued from the study prior to Week 24 post-HSCT or had a missing outcome at Week 24 post-HSCT were counted as failures.</p><p><strong><u>&nbsp;</u></strong></p><p>Letermovir demonstrated superior efficacy over placebo in the analysis of the primary endpoint, as shown in Table 3. The estimated treatment difference of -23.5% was statistically significant (one-sided p‑value &lt;0.0001).</p><p>&nbsp;</p><p><strong>Table 3:</strong> <strong>P001: Efficacy results</strong> <strong>in HSCT recipients (NC=F Approach, FAS Population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(N=325)</p></td><td style="vertical-align:top"><p>(N=170)</p></td></tr><tr><td style="vertical-align:top"><p>Parameter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>n (%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Primary efficacy endpoint</p><p>(Proportion of subjects who failed prophylaxis by Week 24)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>122 (37.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>103 (60.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Reasons for Failures<sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinically significant CMV infection&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>57 (17.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>71 (41.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; CMV DNAemia warranting anti-CMV PET</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; 52 (16.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; 68 (40.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; CMV end-organ disease&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 5 (1.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 3 (1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued from study&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>56 (17.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>27 (15.9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Missing outcome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; 9 (2.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; 5 (2.9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Stratum-adjusted treatment difference (Letermovir-Placebo)<sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-23.5 (-32.5, -14.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>&dagger;</sup> The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.</p><p><sup>&sect;</sup> 95% CIs and p-value for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (high or low risk). A 1-sided p-value &le;0.0249 was used for declaring statistical significance.</p><p>FAS=Full analysis set; FAS includes randomised subjects who received at least one dose of study medicine, and excludes subjects with detectable CMV DNA at baseline. Approach to handling missing values: Non-Completer=Failure (NC=F) approach. With NC=F approach, failure was defined as all subjects with clinically significant CMV infection or who prematurely discontinued from the study or had a missing outcome through Week 24 post-transplant visit window.</p><p>N=number of subjects in each treatment group.</p><p>n (%)=Number (percent) of subjects in each sub-category.</p><p>Note: The proportion of subjects with detectable CMV viral DNA on Day 1 that developed clinically significant CMV infection in the letermovir group was 64.6% (31/48) compared to 90.9% (20/22) in the placebo group through Week 24 post-HSCT. The estimated difference (95% CI for the difference) was -26.1% (-45.9%, -6.3%), with a nominal one-sided p-value &lt;0.0048.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Factors associated with CMV DNAemia after Week 14 post-HSCT among letermovir-treated subjects included high risk for CMV reactivation at baseline, GVHD, use of corticosteroids, and CMV negative donor serostatus.</p><p>&nbsp;</p><p><strong>Figure 1: P001: Kaplan-Meier plot of time to initiation of anti-CMV PET or onset of CMV end-organ disease through Week 24 post-transplant in HSCT recipients (FAS population)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_757" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:445.5pt;height:383.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title="" croptop="7046f" cropbottom="11236f" cropleft="8435f" cropright="16678f"/>
</v:shape><![endif]--><img width="594" height="511" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>There were no differences in the incidence of or time to engraftment between the PREVYMIS and placebo groups.</p><p>&nbsp;</p><p>Efficacy consistently favoured letermovir across subgroups including low and high risk for CMV reactivation, conditioning regimens, and concomitant immunosuppressive regimens (see Figure 2).</p><p>&nbsp;</p><p><strong>Figure 2: P001: Forest plot of the proportion of subjects initiating anti-CMV PET or with CMV end-organ disease through Week 24 post-HSCT by selected subgroups (NC=F approach, FAS population)</strong></p><p><strong><u>&nbsp;</u></strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Canvas_x0020_938" o:spid="_x0000_s1026"
 editas="canvas" style='width:468pt;height:361.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="59436,45910" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  width:59436;height:45910;visibility:visible;mso-wrap-style:square'>
  <v:fill o:detectmouseclick="t"/>
  <v:path o:connecttype="none"/>
 </v:shape><v:rect id="Rectangle_x0020_5" o:spid="_x0000_s1028" style='position:absolute;
  left:27051;top:36715;width:26949;height:7;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" strokeweight=".55pt"/>
 <v:line id="Line_x0020_6" o:spid="_x0000_s1029" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="29476,36722" to="29476,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_7" o:spid="_x0000_s1030" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="31934,36722" to="31934,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_8" o:spid="_x0000_s1031" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="34378,36722" to="34378,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_9" o:spid="_x0000_s1032" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="36836,36722" to="36836,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_10" o:spid="_x0000_s1033" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="39293,36722" to="39293,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:line id="Line_x0020_11" o:spid="_x0000_s1034" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="41751,36722" to="41751,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_12" o:spid="_x0000_s1035" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="44208,36722" to="44208,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCcaUfgxAAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvBf/D8oTemk0VbEhdpQgWKXgwiujtNftMQrJvQ3Yb4793BaHHYWa+YebLwTSip85VlhW8RzEI
4tzqigsFh/36LQHhPLLGxjIpuJGD5WL0MsdU2yvvqM98IQKEXYoKSu/bVEqXl2TQRbYlDt7FdgZ9
kF0hdYfXADeNnMTxTBqsOCyU2NKqpLzO/oyC+lufz7+1HuqPo8Wf7Y2b04WVeh0PX58gPA3+P/xs
b7SCZDqBx5lwBOTiDgAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJxpR+DEAAAA3AAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_13" o:spid="_x0000_s1036" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="46672,36722" to="46672,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_14" o:spid="_x0000_s1037" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="49117,36722" to="49117,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_15" o:spid="_x0000_s1038" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="51574,36722" to="51574,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:rect id="Rectangle_x0020_16" o:spid="_x0000_s1039" style='position:absolute;
  left:28581;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-70</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_17" o:spid="_x0000_s1040" style='position:absolute;
  left:31045;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBpYbuJwgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvhb5DOAXvNFsFXVajFEGwxRtXH+CwOfuDycmSRHf79k2h4OUwM98w2/1ojXiSD51jBR/zDARx
5XTHjYLb9TjLQYSIrNE4JgU/FGC/e5tssdBu4As9y9iIBOFQoII2xr6QMlQtWQxz1xMnr3beYkzS
N1J7HBLcGrnIspW02HFaaLGnQ0vVvXxYBfJaHoe8ND5z34v6bL5Ol5qcUtP38XMDItIYX+H/9kkr
yJdr+DuTjoDc/QIAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBpYbuJwgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-60</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_18" o:spid="_x0000_s1041" style='position:absolute;
  left:33489;top:38087;width:1658;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-50</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_19" o:spid="_x0000_s1042" style='position:absolute;
  left:35947;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-40</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_20" o:spid="_x0000_s1043" style='position:absolute;
  left:38404;top:38087;width:1658;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-30</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_21" o:spid="_x0000_s1044" style='position:absolute;
  left:40862;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDRwvUbwQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/disIw
FITvF3yHcATv1lSRpVSjiCC4sjdWH+DQnP5gclKSrK1vb4SFvRxm5htmsxutEQ/yoXOsYDHPQBBX
TnfcKLhdj585iBCRNRrHpOBJAXbbyccGC+0GvtCjjI1IEA4FKmhj7AspQ9WSxTB3PXHyauctxiR9
I7XHIcGtkcss+5IWO04LLfZ0aKm6l79WgbyWxyEvjc/ceVn/mO/TpSan1Gw67tcgIo3xP/zXPmkF
+WoB7zPpCMjtCwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhANHC9RvBAAAA3AAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-20</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_22" o:spid="_x0000_s1045" style='position:absolute;
  left:43319;top:38087;width:1658;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-10</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_23" o:spid="_x0000_s1046" style='position:absolute;
  left:46323;top:38087;width:641;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>0</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_24" o:spid="_x0000_s1047" style='position:absolute;
  left:48418;top:38087;width:1277;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>10</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_25" o:spid="_x0000_s1048" style='position:absolute;
  left:50876;top:38087;width:1276;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>20</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_26" o:spid="_x0000_s1049" style='position:absolute;
  left:17291;top:41148;width:28359;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='color:black'>Letermovir -
     Placebo Difference (%) and 95% C.I.</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_27" o:spid="_x0000_s1050" style='position:absolute;
  left:38677;top:3873;width:4407;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_28" o:spid="_x0000_s1051" style='position:absolute;
  left:38608;top:3562;width:152;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_29" o:spid="_x0000_s1052" style='position:absolute;
  left:43014;top:3562;width:153;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_30" o:spid="_x0000_s1053" style='position:absolute;
  left:34994;top:7385;width:8008;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_31" o:spid="_x0000_s1054" style='position:absolute;
  left:34925;top:7073;width:152;height:788;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_32" o:spid="_x0000_s1055" style='position:absolute;
  left:42932;top:7073;width:152;height:788;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_33" o:spid="_x0000_s1056" style='position:absolute;
  left:38976;top:8547;width:5283;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_34" o:spid="_x0000_s1057" style='position:absolute;
  left:38906;top:8242;width:152;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB82iydxgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvQr9DeIXeNKuorKtRtFDopeCfHurtuXnuLm5e1iTVbT+9EQSPw8z8hpktWlOLCzlfWVbQ7yUg
iHOrKy4UfO8+uikIH5A11pZJwR95WMxfOjPMtL3yhi7bUIgIYZ+hgjKEJpPS5yUZ9D3bEEfvaJ3B
EKUrpHZ4jXBTy0GSjKXBiuNCiQ29l5Sftr9GwWqSrs7rIX/9bw572v8cTqOBS5R6e22XUxCB2vAM
P9qfWkE6GsL9TDwCcn4DAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAfNosncYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_35" o:spid="_x0000_s1058" style='position:absolute;
  left:44189;top:8242;width:153;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_36" o:spid="_x0000_s1059" style='position:absolute;
  left:38169;top:12065;width:5309;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_37" o:spid="_x0000_s1060" style='position:absolute;
  left:38093;top:11753;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_38" o:spid="_x0000_s1061" style='position:absolute;
  left:43402;top:11753;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_39" o:spid="_x0000_s1062" style='position:absolute;
  left:35960;top:13239;width:8915;height:153;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_40" o:spid="_x0000_s1063" style='position:absolute;
  left:35890;top:12928;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_41" o:spid="_x0000_s1064" style='position:absolute;
  left:44805;top:12928;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_42" o:spid="_x0000_s1065" style='position:absolute;
  left:39985;top:16751;width:7684;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_43" o:spid="_x0000_s1066" style='position:absolute;
  left:39916;top:16440;width:152;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_44" o:spid="_x0000_s1067" style='position:absolute;
  left:47593;top:16440;width:159;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_45" o:spid="_x0000_s1068" style='position:absolute;
  left:30600;top:17913;width:11868;height:159;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_46" o:spid="_x0000_s1069" style='position:absolute;
  left:30530;top:17608;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_47" o:spid="_x0000_s1070" style='position:absolute;
  left:42392;top:17608;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_48" o:spid="_x0000_s1071" style='position:absolute;
  left:35591;top:19088;width:6922;height:158;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_49" o:spid="_x0000_s1072" style='position:absolute;
  left:35521;top:18783;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_50" o:spid="_x0000_s1073" style='position:absolute;
  left:42443;top:18783;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_51" o:spid="_x0000_s1074" style='position:absolute;
  left:38119;top:20256;width:12598;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_52" o:spid="_x0000_s1075" style='position:absolute;
  left:38049;top:19945;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_53" o:spid="_x0000_s1076" style='position:absolute;
  left:50647;top:19945;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_54" o:spid="_x0000_s1077" style='position:absolute;
  left:30695;top:23768;width:12415;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_55" o:spid="_x0000_s1078" style='position:absolute;
  left:30626;top:23456;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_56" o:spid="_x0000_s1079" style='position:absolute;
  left:43033;top:23456;width:159;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_57" o:spid="_x0000_s1080" style='position:absolute;
  left:39071;top:24942;width:4750;height:153;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_58" o:spid="_x0000_s1081" style='position:absolute;
  left:39001;top:24638;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_59" o:spid="_x0000_s1082" style='position:absolute;
  left:43751;top:24638;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_60" o:spid="_x0000_s1083" style='position:absolute;
  left:38334;top:28448;width:6389;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_61" o:spid="_x0000_s1084" style='position:absolute;
  left:38265;top:28136;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_62" o:spid="_x0000_s1085" style='position:absolute;
  left:44653;top:28136;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_63" o:spid="_x0000_s1086" style='position:absolute;
  left:37407;top:29622;width:8719;height:153;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_64" o:spid="_x0000_s1087" style='position:absolute;
  left:37338;top:29311;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_65" o:spid="_x0000_s1088" style='position:absolute;
  left:46050;top:29311;width:158;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_66" o:spid="_x0000_s1089" style='position:absolute;
  left:34048;top:30797;width:8928;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_67" o:spid="_x0000_s1090" style='position:absolute;
  left:33972;top:30486;width:159;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDyaJ6txgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvQv/D8gq9mU3FtjG6ShUKvQhqPejtmX1Ngtm36e5WU3+9KxQ8DjPzDTOZdaYRJ3K+tqzgOUlB
EBdW11wq2H599DMQPiBrbCyTgj/yMJs+9CaYa3vmNZ02oRQRwj5HBVUIbS6lLyoy6BPbEkfv2zqD
IUpXSu3wHOGmkYM0fZUGa44LFba0qKg4bn6Ngvkom/+shry8rA972u8Ox5eBS5V6euzexyACdeEe
/m9/agVZ9ga3M/EIyOkVAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA8miercYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_68" o:spid="_x0000_s1091" style='position:absolute;
  left:42906;top:30486;width:153;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_69" o:spid="_x0000_s1092" style='position:absolute;
  left:36055;top:34296;width:5950;height:159;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_70" o:spid="_x0000_s1093" style='position:absolute;
  left:35979;top:33991;width:158;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_71" o:spid="_x0000_s1094" style='position:absolute;
  left:41929;top:33991;width:158;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_72" o:spid="_x0000_s1095" style='position:absolute;
  left:39344;top:35477;width:7055;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_73" o:spid="_x0000_s1096" style='position:absolute;
  left:39274;top:35166;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_74" o:spid="_x0000_s1097" style='position:absolute;
  left:46323;top:35166;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:shape id="Freeform_x0020_75" o:spid="_x0000_s1098" style='position:absolute;
  left:40519;top:3575;width:762;height:755;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_76" o:spid="_x0000_s1099" style='position:absolute;
  left:38620;top:7086;width:756;height:762;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r59,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_77" o:spid="_x0000_s1100" style='position:absolute;
  left:41230;top:8248;width:762;height:762;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_78" o:spid="_x0000_s1101" style='position:absolute;
  left:40436;top:11766;width:756;height:756;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m60,r59,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_79" o:spid="_x0000_s1102" style='position:absolute;
  left:40043;top:12941;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_80" o:spid="_x0000_s1103" style='position:absolute;
  left:43465;top:16452;width:756;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r59,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_81" o:spid="_x0000_s1104" style='position:absolute;
  left:36163;top:17621;width:755;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m59,r60,59l59,119,,59,59,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_82" o:spid="_x0000_s1105" style='position:absolute;
  left:38665;top:18796;width:762;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_83" o:spid="_x0000_s1106" style='position:absolute;
  left:44024;top:19958;width:756;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m59,r60,60l59,120,,60,59,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_84" o:spid="_x0000_s1107" style='position:absolute;
  left:36531;top:23469;width:756;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m59,r60,60l59,120,,60,59,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_85" o:spid="_x0000_s1108" style='position:absolute;
  left:41052;top:24644;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_86" o:spid="_x0000_s1109" style='position:absolute;
  left:41148;top:28149;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_87" o:spid="_x0000_s1110" style='position:absolute;
  left:41395;top:29324;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_88" o:spid="_x0000_s1111" style='position:absolute;
  left:38131;top:30499;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_89" o:spid="_x0000_s1112" style='position:absolute;
  left:38639;top:34004;width:762;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_90" o:spid="_x0000_s1113" style='position:absolute;
  left:42475;top:35179;width:762;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:rect id="Rectangle_x0020_91" o:spid="_x0000_s1114" style='position:absolute;
  left:46634;top:1612;width:57;height:35110;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="#0080ff" strokecolor="#0080ff" strokeweight=".55pt"/>
 <v:rect id="Rectangle_x0020_92" o:spid="_x0000_s1115" style='position:absolute;
  left:37274;top:39604;width:8934;height:1436;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f"/>
 <v:rect id="Rectangle_x0020_93" o:spid="_x0000_s1116" style='position:absolute;
  left:37820;top:39738;width:7188;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:7.0pt;color:black'>Favors
     Letermovir</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_94" o:spid="_x0000_s1117" style='position:absolute;
  left:12280;top:34893;width:9691;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCk53YDwgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NigIx
EITvgu8QWvCmGUUWdzSKCIIuXhz3AZpJzw8mnSHJOrNvbxaEPRZV9RW13Q/WiCf50DpWsJhnIIhL
p1uuFXzfT7M1iBCRNRrHpOCXAux349EWc+16vtGziLVIEA45Kmhi7HIpQ9mQxTB3HXHyKuctxiR9
LbXHPsGtkcss+5AWW04LDXZ0bKh8FD9WgbwXp35dGJ+5r2V1NZfzrSKn1HQyHDYgIg3xP/xun7WC
z8UK/s6kIyB3LwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCk53YDwgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Tacrolimus
     (n=145, 69)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_95" o:spid="_x0000_s1118" style='position:absolute;
  left:47002;top:39604;width:7728;height:1436;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" stroked="f"/>
 <v:rect id="Rectangle_x0020_96" o:spid="_x0000_s1119" style='position:absolute;
  left:47548;top:39738;width:5804;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:7.0pt;color:black'>Favors
     Placebo</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_97" o:spid="_x0000_s1120" style='position:absolute;
  left:12280;top:29038;width:17253;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Reduced
     intensity conditioning (n=86, 48)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_98" o:spid="_x0000_s1121" style='position:absolute;
  left:12280;top:33718;width:11018;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Cyclosporin
     A (n=162, 90)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_99" o:spid="_x0000_s1122" style='position:absolute;
  left:9823;top:22009;width:8611;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Haploidentical
     donor</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_100" o:spid="_x0000_s1123" style='position:absolute;
  left:12280;top:30213;width:12396;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Non-myeloablative
     (n=85, 37)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_101" o:spid="_x0000_s1124" style='position:absolute;
  left:9823;top:32550;width:12109;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Immunosuppressive
     Regimen</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_102" o:spid="_x0000_s1125" style='position:absolute;
  left:9823;top:26701;width:9290;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Conditioning
     Regimen</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_103" o:spid="_x0000_s1126" style='position:absolute;
  left:12280;top:27863;width:10929;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Myeloablative
     (n=154, 85)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_104" o:spid="_x0000_s1127" style='position:absolute;
  left:12280;top:24358;width:6814;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBqi7y+wgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvC75DOIJ3NesiRVejiCBo6Y2rD3DYnP3B5GRJUnf79qZQ6OUwM98w2/1ojXiSD51jBYt5BoK4
crrjRsH9dnpfgQgRWaNxTAp+KMB+N3nbYqHdwFd6lrERCcKhQAVtjH0hZahashjmridOXu28xZik
b6T2OCS4NTLPsg9pseO00GJPx5aqR/ltFchbeRpWpfGZ+8zrL3M5X2tySs2m42EDItIY/8N/7bNW
sM6X8HsmHQG5ewEAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBqi7y+wgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>No
     (n=276, 153)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_105" o:spid="_x0000_s1128" style='position:absolute;
  left:12280;top:23183;width:6135;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Yes
     (n=49, 17)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_106" o:spid="_x0000_s1129" style='position:absolute;
  left:12280;top:19672;width:13608;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Mismatched
     unrelated (n=43, 24)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_107" o:spid="_x0000_s1130" style='position:absolute;
  left:12280;top:17068;width:12592;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Mismatched
     related (n=52, 18)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_108" o:spid="_x0000_s1131" style='position:absolute;
  left:12268;top:18116;width:12649;height:1651;rotation:-1;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Matched
     unrelated (n=122, 70)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_109" o:spid="_x0000_s1132" style='position:absolute;
  left:12280;top:15906;width:11634;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Matched
     related (n=108, 58)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_110" o:spid="_x0000_s1133" style='position:absolute;
  left:9823;top:14992;width:6801;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Donor
     mismatch </span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_111" o:spid="_x0000_s1134" style='position:absolute;
  left:12280;top:12655;width:10116;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Bone
     marrow (n=72, 43)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_112" o:spid="_x0000_s1135" style='position:absolute;
  left:12280;top:11480;width:12313;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Peripheral
     blood (n=241, 117)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_113" o:spid="_x0000_s1136" style='position:absolute;
  left:9823;top:10312;width:8293;height:1651;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Stem
     Cell Source</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_114" o:spid="_x0000_s1137" style='position:absolute;
  left:12280;top:6800;width:9214;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>High
     Risk (n=102, 45)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_115" o:spid="_x0000_s1138" style='position:absolute;
  left:12280;top:7962;width:9805;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Low
     Risk<span style='mso-spacerun:yes'>  </span>(n=223, 125)</span><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_116" o:spid="_x0000_s1139" style='position:absolute;
  left:9823;top:5626;width:5169;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Risk
     stratum</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_117" o:spid="_x0000_s1140" style='position:absolute;
  left:9823;top:3289;width:9100;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Overall<span
     style='mso-spacerun:yes'>  </span>(N=325, 170)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="624" height="482" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:468pt;
 height:361.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>NC=F, Non-Completer=Failure. With NC=F approach, subjects who discontinued from the study prior to Week 24 post-transplant or had a missing outcome at Week 24 post-transplant were counted as failures.</p><p>.</p><p><em>&nbsp;</em></p><p><em>P040: Prophylaxis from Week 14 (~100 days) through Week&nbsp;28 (~200 days) post-HSCT</em></p><p>The efficacy of extending letermovir prophylaxis from Week&nbsp;14 (~100 days) through Week&nbsp;28 (~200&nbsp;days) post-HSCT in patients at risk for late CMV infection and disease was assessed in a multicentre, double-blind, placebo-controlled Phase 3 trial (P040) in adult CMV-seropositive recipients [R+] of an allogeneic HSCT. Eligible subjects who completed letermovir prophylaxis through ~100&nbsp;days post-HSCT were randomised (2:1) to receive letermovir or placebo from Week 14 through Week&nbsp;28 post-HSCT. Subjects were monitored through Week&nbsp;28 post-HSCT for the primary efficacy endpoint with continued off-treatment follow-up through Week&nbsp;48 post-HSCT.</p><p>&nbsp;</p><p>Among the 218 treated subjects, 144 subjects received letermovir and 74 received placebo. The median age was 55 years (range: 20 to 74 years); 62% were male; 79% were white; 11% were Asian; 2% were Black; and 10% were Hispanic or Latino. The most common reasons for transplant were acute myeloid leukaemia (42%), acute lymphocytic leukaemia (15%), and myelodysplastic syndrome (11%).</p><p>&nbsp;</p><p>At study entry, all subjects had risk factors for late CMV infection and disease, with 64% having two or more risk factors. The risk factors included: HLA-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B or -DR; haploidentical donor; unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and ‑DRB1; use of umbilical cord blood as stem cell source; use of <em>ex</em> <em>vivo</em> T-cell-depleted grafts; receipt of anti-thymocyte globulin; receipt of alemtuzumab; use of systemic prednisone (or equivalent) at a dose of &ge;1&nbsp;mg/kg of body weight per day.</p><p>&nbsp;</p><p><em>Primary efficacy endpoint</em></p><p>The primary efficacy endpoint of P040 was the incidence of clinically significant CMV infection through Week 28 post-HSCT. Clinically significant CMV infection was defined as the occurrence of either CMV end-organ disease, or initiation of anti-CMV PET based on documented CMV viremia and the clinical condition of the subject. The Observed Failure (OF) approach was used, where subjects who developed clinically significant CMV infection or discontinued prematurely from the study with viremia were counted as failures.</p><p>&nbsp;</p><p>Letermovir demonstrated superior efficacy over placebo in the analysis of the primary endpoint, as shown in Table 4. The estimated treatment difference of -16.1% was statistically significant (one-sided p-value=0.0005). Efficacy consistently favored letermovir across subgroups based on subject characteristics (age, gender, race) and risk factors for late CMV infection and disease.</p><p>&nbsp;</p><p><strong>Table 4: P040: Efficacy results in HSCT recipients at risk for late CMV infection and disease (OF approach, FAS population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>Letermovir</strong><br /><strong>(~200 days </strong><strong>letermovir</strong><strong>)<br />(N=144)<br />n (%)</strong></p></td><td><p><strong>Placebo<br />(~100 days </strong><strong>letermovir</strong><strong>)<br />(N=74)<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Failures*</strong></p></td><td style="vertical-align:top"><p><strong>4 (2.8)</strong></p></td><td style="vertical-align:top"><p><strong>14 (18.9)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinically significant CMV infection through Week 28<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>2 (1.4)</p></td><td style="vertical-align:top"><p>13 (17.6)</p></td></tr><tr><td style="vertical-align:top"><p>Initiation of PET based on documented CMV viremia</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 1 (0.7)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 11 (14.9)</p></td></tr><tr><td style="vertical-align:top"><p>CMV end-organ disease</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 1 (0.7)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued from study with CMV viremia before Week 28</p></td><td style="vertical-align:top"><p>2 (1.4)</p></td><td style="vertical-align:top"><p>1 (1.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stratum-adjusted treatment difference (</strong><strong>letermovir (~200 days letermovir)-Placebo (~100 days letermovir))<sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>-16.1 (-25.8, -6.5)</p><p>0.0005</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.</p><p><sup>&dagger;</sup> Clinically significant CMV infection was defined as CMV end-organ disease (proven or probable) or initiation of PET based on documented CMV viremia and the clinical condition of the subject.</p><p><sup>&Dagger;</sup> 95% CIs and p-value for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (haploidentical donor yes or no). A one-sided p-value &le;0.0249 was used for declaring statistical significance.</p><p>Approach to handling missing values: Observed Failure (OF) approach. With the OF approach, failure was defined as all subjects who developed clinically significant CMV infection or discontinued prematurely from the study with CMV viremia from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT.</p><p>N=Number of subjects in each treatment group.</p><p>n (%)=Number (percent) of subjects in each sub-category.</p></td></tr></tbody></table><p><!--[if supportFields]><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='mso-element:field-begin'></span></span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'><span
style='mso-spacerun:yes'> </span>INCLUDETEXT
&quot;\\\\bardsar-prod\\mk8228-cytomegalovirus\\prot001-csr\\outgraph\\pr0km0plot0cmvinfc0w24.rtf&quot;
\c MSRTF<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-separator'></span></span><![endif]--></p><p><!--[if supportFields]><span lang=EN-GB><span
style='mso-element:field-end'></span></span><![endif]-->P002: <em>Adult CMV-seronegative recipients of a kidney transplant from a CMV-seropositive donor [D+/R-]</em></p><p>To evaluate letermovir prophylaxis as a preventive strategy for CMV disease in kidney transplant recipients, the efficacy of letermovir was assessed in a multicentre, double-blind, active comparator-controlled non-inferiority Phase 3 trial (P002) in adult kidney transplant recipients at high risk [D+/R‑]. Subjects were randomised (1:1) to receive either letermovir or valganciclovir. Letermovir was given concomitantly with acyclovir. Valganciclovir was given concomitantly with a placebo to acyclovir. Randomisation was stratified by the use or non-use of highly cytolytic, anti-lymphocyte immunotherapy during induction. Letermovir or valganciclovir were initiated between Day 0 and Day 7 post-kidney transplant and continued through Week 28 (~200 days) post-transplant. Subjects were monitored through Week 52 post-transplant.</p><p>&nbsp;</p><p>Among the 589 treated subjects, 292 subjects received letermovir and 297 received valganciclovir. The median age was 51 years (range: 18 to 82 years); 72% were male; 84% were White; 2% were Asian; 9% were Black; 17% were Hispanic or Latino; and 60% received a kidney from a deceased donor. The most common primary reasons for transplant were congenital cystic kidney disease (17%), hypertension (16%), and diabetes/diabetic nephropathy (14%).</p><p>&nbsp;</p><p><em>Primary efficacy endpoint</em></p><p>The primary efficacy endpoint of P002 was the incidence of CMV disease (CMV end-organ disease or CMV syndrome, confirmed by an independent adjudication committee) through Week 52 post-transplant. The OF approach was used, where subjects who discontinued prematurely from the study for any reason or were missing data at the timepoint were not considered failures.</p><p>&nbsp;</p><p>Letermovir demonstrated non-inferiority to valganciclovir in the analysis of the primary endpoint, as shown in Table 5.</p><p>&nbsp;</p><p><strong>Table 5: P002 Efficacy results in kidney transplant recipients (OF approach, FAS population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>Letermovir</strong><br /><strong>(N=289)<br />n (%)</strong></p></td><td><p><strong>Valganciclovir<br />(N=297)<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>CMV disease* through Week 52</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>30 (10.4)</strong></p></td><td style="vertical-align:top"><p><strong>35 (11.8)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Stratum-adjusted treatment difference (Letermovir-Valganciclovir)<sup>&dagger;</sup></strong></p><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>-1.4 (-6.5, 3.8)<sup>&Dagger;</sup></p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* CMV disease cases confirmed by an independent adjudication committee.</p><p><sup>&dagger;</sup> The 95% CIs for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (use/nonuse of highly cytolytic, anti-lymphocyte immunotherapy during induction).</p><p><sup>&Dagger;</sup> Based on a non-inferiority margin of 10%, letermovir is non-inferior to valganciclovir.</p><p>Approach to handling missing values: Observed Failure (OF) approach. With OF approach, participants who discontinue prematurely from the study for any reason are not considered failures.</p><p>Note: Subjects randomised to the letermovir group were given acyclovir for herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis. Subjects randomised to the valganciclovir group were given a placebo to acyclovir.</p><p>N=number of subjects in each treatment group.</p><p>n (%)=Number (percent) of subjects in each sub-category.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was comparable across all subgroups, including sex, age, race, region, and the use/non-use of highly cytolytic, anti-lymphocyte immunotherapy during induction.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with PREVYMIS in one or more subsets of the paediatric population for prophylaxis of cytomegalovirus infection (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects, the pharmacokinetics of letermovir have been characterised following oral and intravenous administration. Letermovir exposure increased in a greater than dose-proportional manner with both oral or intravenous administration. The mechanism is likely saturation/autoinhibition of OATP1B1/3. The pharmacokinetics of letermovir have also been characterised following oral and intravenous administration in HSCT recipients (Table 6) and following oral administration in kidney transplant recipients (Table 7).</p><p>&nbsp;</p><p><em>Healthy</em><em> subjects</em></p><p>The geometric mean steady-state AUC and C<sub>max</sub> values were 71,500&nbsp;ng&bull;hr/mL and 13,000&nbsp;ng/mL, respectively, with 480&nbsp;mg once daily oral letermovir.</p><p>&nbsp;</p><p>Letermovir reached steady-state in 9 to 10 days with an accumulation ratio of 1.2 for AUC and 1 for C<sub>max</sub>.</p><p>&nbsp;</p><p><em>HSCT recipients</em></p><p>Letermovir AUC was estimated using population pharmacokinetic analyses using P001 Phase 3 data (see Table 6). Differences in exposure across treatment regimens are not clinically relevant; efficacy was consistent across the range of exposures observed in P001.</p><p>&nbsp;</p><p><strong>Table </strong><strong>6</strong><strong>: Letermovir AUC (ng&bull;hr/mL) values in HSCT Recipients</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:101%"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Median (90% Prediction Interval)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>480&nbsp;mg Oral, no cyclosporine</p></td><td style="vertical-align:top"><p>34,400 (16,900, 73,700)</p></td></tr><tr><td style="vertical-align:top"><p>480&nbsp;mg intravenous, no cyclosporine</p></td><td style="vertical-align:top"><p>100,000 (65,300, 148,000)</p></td></tr><tr><td style="vertical-align:top"><p>240&nbsp;mg Oral, with cyclosporine</p></td><td style="vertical-align:top"><p>60,800 (28,700, 122,000)</p></td></tr><tr><td style="vertical-align:top"><p>240&nbsp;mg intravenous, with cyclosporine</p></td><td style="vertical-align:top"><p>70,300 (46,200, 106,000)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Population post-hoc predictions from the population PK analysis using Phase 3 data</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Kidney transplant recipients</em></p><p>Letermovir AUC was estimated using population pharmacokinetic analysis using P002 Phase 3 data (see Table 7). Efficacy was consistent across the range of exposures observed in P002.</p><p>Table 7: Letermovir AUC (ng&bull;hr/mL) values in kidney transplant recipients</p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Median (90% Prediction Interval)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>480&nbsp;mg Oral, no cyclosporine</p></td><td style="vertical-align:top"><p>62,200 (28,900, 145,000)</p></td></tr><tr><td style="vertical-align:top"><p>240&nbsp;mg Oral, with cyclosporine</p></td><td style="vertical-align:top"><p>57,700 (26,900, 135,000)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Medians and 90% prediction intervals are based on simulations using the Phase 3 population PK model with inter-individual variability.</p><p>Note: PK of letermovir was not studied following IV administration in kidney transplant recipients; however, the projected AUC following IV administration is similar to the model predicted AUC following IV administration in HSCT recipients (Table 6).</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Letermovir was absorbed rapidly with a median time to maximum plasma concentration (T<sub>max</sub>) of 1.5 to 3.0 hours and declined in a biphasic manner. In HSCT recipients, bioavailability of letermovir was estimated to be approximately 35% with 480&nbsp;mg once daily oral letermovir administered without cyclosporine. The inter-individual variability for bioavailability was estimated to be approximately 37%. In kidney transplant recipients, bioavailability of letermovir was estimated to be approximately 60% with 480&nbsp;mg once daily oral letermovir administered without cyclosporine.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Effect of cyclosporine</em></p><p>In HSCT recipients, co-administration of cyclosporine increased plasma concentrations of letermovir due to inhibition of OATP1B. Bioavailability of letermovir was estimated to be approximately 85% with 240&nbsp;mg once daily oral letermovir co-administered with cyclosporine in patients.</p><p>If letermovir is co-administered with cyclosporine, the recommended dose of letermovir is 240&nbsp;mg once daily (see section 4.2).</p><p>&nbsp;</p><p><em>Effect of food</em></p><p>In healthy subjects, oral administration of 480&nbsp;mg single dose of letermovir with a standard high fat and high calorie meal did not have any effect on the overall exposure (AUC) and resulted in approximately 30% increase in peak levels (C<sub>max</sub>) of letermovir. Letermovir may be administered orally with or without food as has been done in the clinical trials (see section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Based on population pharmacokinetic analyses, the mean steady-state volume of distribution is estimated to be 45.5&nbsp;L following intravenous administration in HSCT recipients.</p><p>&nbsp;</p><p>Letermovir is extensively bound (98.2%) to human plasma proteins, independent of the concentration range (3 to 100&nbsp;mg/L) evaluated, <em>in vitro</em>. Some saturation was observed at lower concentrations. Blood to plasma partitioning of letermovir is 0.56 and independent of the concentration range (0.1 to 10&nbsp;mg/L) evaluated <em>in vitro</em>.</p><p>&nbsp;</p><p>In preclinical distribution studies, letermovir is distributed to organs and tissues with the highest concentrations observed in the gastrointestinal tract, bile duct and liver and low concentrations in the brain.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The majority of letermovir-related components in plasma is unchanged parent (96.6%). No major metabolites are detected in plasma. Letermovir is partly eliminated by glucuronidation mediated by UGT1A1/1A3.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Elimination</u></p><p>&nbsp;</p><p>The mean apparent terminal half-life for letermovir is approximately 12&nbsp;hours with 480&nbsp;mg intravenous letermovir in healthy subjects. The major elimination pathways of letermovir is biliary excretion as well as direct glucuronidation. The process involves the hepatic uptake transporters OATP1B1 and 3 followed by UGT1A1/3 catalysed glucuronidation.</p><p>&nbsp;</p><p>Based on population pharmacokinetic analyses, letermovir steady-state apparent CL is estimated to be 4.84&nbsp;L/hr following intravenous administration of 480&nbsp;mg in HSCT recipients. The inter-individual variability for CL is estimated to be 24.6%.</p><p><u>&nbsp;</u></p><p><u>Excretion</u></p><p>&nbsp;</p><p>After oral administration of radio-labeled letermovir, 93.3% of radioactivity was recovered in faeces. The majority of letermovir was biliary excreted as unchanged parent with a minor amount (6% of dose) as an acyl-glucuronide metabolite in faeces. The acyl-glucuronide is unstable in faeces. Urinary excretion of letermovir was negligible (&lt;2% of dose).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Pharmacokinetics in special populations</u></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Letermovir unbound AUC was approximately 81%- and 4-fold higher in subjects with moderate (Child-Pugh Class B [CP-B], score of 7-9) and severe (Child-Pugh Class C [CP-C], score of 10-15) hepatic impairment, respectively, compared to healthy subjects. The changes in letermovir exposure in subjects with moderate hepatic impairment are not clinically relevant.</p><p>&nbsp;</p><p>Marked increases in letermovir unbound exposure are anticipated in patients with moderate hepatic impairment combined with moderate or severe renal impairment (see section 4.2).</p><p><strong><u>&nbsp;</u></strong></p><p><em>Renal impairment</em></p><p><em>Clinical study in a renally impaired population</em></p><p>Letermovir unbound AUC was approximately 115- and 81% higher in subjects with moderate (eGFR of 31 to 56.8&nbsp;mL/min/1.73m<sup>2</sup>) and severe (eGFR of 11.9 to 28.1&nbsp;mL/min/1.73m<sup>2</sup>) renal impairment, respectively, compared to healthy subjects. The changes in letermovir exposure due to moderate or severe renal impairment are not considered to be clinically relevant. Subjects with ESRD have not been studied.</p><p>&nbsp;</p><p><em>Post-kidney transplant (P002)</em></p><p>Based on population pharmacokinetic analysis, letermovir AUC was approximately 12%, 27% and 35% higher in subjects with mild (CrCl greater than or equal to 60 to less than 90&nbsp;mL/min), moderate (CrCl greater than or equal to 30 to less than 60&nbsp;mL/min) and severe (CrCl greater than or equal to 15 to less than 30&nbsp;mL/min) renal impairment, respectively, compared to subjects with CrCl greater than or equal to 90&nbsp;mL/min. These changes are not considered to be clinically relevant.</p><p>&nbsp;</p><p><em>Weight</em></p><p>Based on population pharmacokinetic analyses in healthy subjects, letermovir AUC is estimated to be 18.7% lower in subjects weighing 80-100&nbsp;kg compared to subjects weighing 67&nbsp;kg. Based on population pharmacokinetic analysis in kidney transplant recipients (P002), letermovir AUC is estimated to be 26% lower in subjects weighing greater than 80&nbsp;kg compared to subjects weighing less than or equal to 80&nbsp;kg. These differences are not clinically relevant.</p><p>&nbsp;</p><p><em>Race</em></p><p>Based on population pharmacokinetic analyses in healthy subjects, letermovir AUC is estimated to be 33.2% higher in Asians compared to Whites. This change is not clinically relevant.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Gender</em></p><p>Based on population pharmacokinetic analyses, there is no difference in letermovir pharmacokinetics in females compared to males.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Based on population pharmacokinetic analyses, there is no effect of age on letermovir pharmacokinetics. No dose adjustment is required based on age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General toxicity</u></p><p>&nbsp;</p><p>Irreversible testicular toxicity was noted only in rats at systemic exposures (AUC) &ge;3-fold the exposures in humans at the recommended human dose (RHD). This toxicity was characterised by seminiferous tubular degeneration, and oligospermia and cell debris in the epididymides, with decreased testicular and epididymides weights. There was no testicular toxicity in rats at exposures (AUC) similar to the exposures in humans at the RHD. Testicular toxicity was not observed in mice and monkeys at the highest doses tested at exposures up to 4-fold and 2-fold, respectively, the exposures in humans at the RHD. The relevance to humans is unknown.</p><p>&nbsp;</p><p>It is known that hydroxypropylbetadex can cause kidney vacuolation in rats when given intravenously at doses greater than 50&nbsp;mg/kg/day. Vacuolation was noted in the kidneys of rats administered intravenous letermovir formulated with 1500&nbsp;mg/kg/day of the cyclodextrin excipient hydroxypropylbetadex.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Carcinogenesis</u></p><p>&nbsp;</p><p>A 6-month oral carcinogenicity study in RasH2 transgenic (Tg.RasH2) mice showed no evidence of human-relevant tumorigenesis up to the highest doses tested, 150&nbsp;mg/kg/day and 300&nbsp;mg/kg/day in males and females, respectively.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>&nbsp;</p><p>Letermovir was not genotoxic in a battery of<em> in vitro</em> or <em>in vivo</em> assays, including microbial mutagenesis assays, chromosomal aberration in Chinese Hamster Ovary cells, and in an <em>in vivo</em> mouse micronucleus study.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Reproduction</u></p><p><em>&nbsp;</em></p><p><em>Fertility</em></p><p>In the fertility and early embryonic development studies in the rat, there were no effects of letermovir on female fertility. In male rats, reduced sperm concentration, reduced sperm motility, and decreased fertility were observed at systemic exposures &ge; 3-fold the AUC in humans at the RHD (see General toxicity).</p><p>&nbsp;</p><p>In monkeys administered letermovir, there was no evidence of testicular toxicity based on histopathologic evaluation, measurement of testicular size, blood hormone analysis (follicle stimulating hormone, inhibin B and testosterone) and sperm evaluation (sperm count, motility and morphology) at systemic exposures approximately 2-fold the AUC in humans at the RHD.</p><p><u>&nbsp;</u></p><p><u>Development</u></p><p>&nbsp;</p><p>In rats, maternal toxicity (including decrease in body weight gain) was noted at 250&nbsp;mg/kg/day (approximately 11-fold the AUC at the RHD); in the offspring, decreased foetal weight with delayed ossification, slightly oedematous foetuses, and increased incidence of shortened umbilical cords and of variations and malformations in the vertebrae, ribs, and pelvis were observed. No maternal or developmental effects were noted at the dose of 50&nbsp;mg/kg/day (approximately 2.5-fold the AUC at the RHD).</p><p>In rabbits, maternal toxicity (including mortality and abortions) was noted at 225&nbsp;mg/kg/day (approximately 2-fold the AUC at the RHD); in the offspring, an increased incidence of malformations and variations in the vertebrae and ribs were observed.</p><p>In the pre- and post-natal developmental study, letermovir was administered orally to pregnant rats. There was no developmental toxicity observed up to the highest exposure tested (2-fold the AUC at the RHD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Microcrystalline cellulose (E460)</p><p>Croscarmellose sodium (E468)</p><p>Povidone (E1201)</p><p>Colloidal anhydrous silica (E551)</p><p>Magnesium stearate (E470b)</p><p><strong><u>&nbsp;</u></strong></p><p><u>Film-coating</u></p><p>&nbsp;</p><p>Lactose monohydrate</p><p>Hypromellose (E464)</p><p>Titanium dioxide (E171)</p><p>Triacetin (E1518)</p><p>Iron oxide yellow (E172)</p><p>Carnauba wax (E903)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packs of 28x1 tablets in Polyamide/Aluminium/PVC &ndash; Aluminium perforated unit dose blisters</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Merck Sharp & Dohme BV
Waarderweg 39
PO Box 581
2031 BN, 2003 PC
Haarlem
Netherlands

Manufacturer  
MSD International GmbH
T/A MSD Ireland (Ballydine)
Kilsheelan Clonmel,
Co. Tipperary
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>